

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 3 JAN 16 CA/Caplus Company Name Thesaurus enhanced and reloaded
NEWS 4 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 5 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 6 JAN 22 CA/Caplus updated with revised CAS roles
NEWS 7 JAN 22 CA/Caplus enhanced with patent applications from India
NEWS 8 JAN 29 PHAR reloaded with new search and display fields
NEWS 9 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 10 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 11 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 12 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 13 FEB 26 MEDLINE reloaded with enhancements
NEWS 14 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 15 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 16 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 17 FEB 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases
NEWS 18 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 19 MAR 16 CASREACT coverage extended
NEWS 20 MAR 20 MARPAT now updated daily
NEWS 21 MAR 22 LWPI reloaded
NEWS 22 MAR 30 RDISCLOSURE reloaded with enhancements
NEWS 23 APR 02 JICST-EPLUS removed from database clusters and STN
NEWS 24 APR 30 GENBANK reloaded and enhanced with Genome Project ID field
NEWS 25 APR 30 CHEMCATS enhanced with 1.2 million new records
NEWS 26 APR 30 CA/Caplus enhanced with 1870-1889 U.S. patent records
NEWS 27 APR 30 INPADOC replaced by INPADOCDB on STN
NEWS 28 MAY 01 New CAS web site launched
NEWS 29 MAY 08 CA/Caplus Indian patent publication number format defined
NEWS 30 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 31 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 32 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 33 MAY 21 CA/Caplus enhanced with additional kind codes for German patents
NEWS 34 MAY 22 CA/Caplus enhanced with IPC reclassification in Japanese patents

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:40:42 ON 25 MAY 2007

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 11:40:51 ON 25 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23

FILE LAST UPDATED: 24 May 2007 (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> E US2005-523276/AP,PRN 25

E1	1	US2005-523271/AP
E2	1	US2005-523273/AP
E3	1 -->	US2005-523276/AP
E4	0	US2005-523276/PRN
E5	1	US2005-523277/AP
E6	1	US2005-523278/AP
E7	1	US2005-523279/AP
E8	1	US2005-523281/AP
E9	1	US2005-523282/AP
E10	1	US2005-523284/AP
E11	1	US2005-523285/AP
E12	1	US2005-523286/AP
E13	1	US2005-523287/AP

10523276.trn

Page 3

E14	1	US2005-52329/AP
E15	1	US2005-52329/PRN
E16	1	US2005-523290/AP
E17	1	US2005-523291/AP
E18	1	US2005-523292/AP
E19	1	US2005-523295/AP
E20	1	US2005-523301/AP
E21	1	US2005-523302/AP
E22	1	US2005-523304/AP
E23	1	US2005-523306/AP
E24	1	US2005-523308/AP
E25	1	US2005-52331/AP

=> S E3

L1 1 US2005-523276/AP

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

2.95

3.16

FILE 'REGISTRY' ENTERED AT 11:42:15 ON 25 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP.USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

DICTIONARY FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> tra l1 1- /rn

L2 TRANSFER L1 1- TI : 6 TERMS

L3 0 L2/RN

=> tra l1 1- rn


L4 TRANSFER L1 1- RN : 23 TERMS

L5 23 L4

=> d scan

10523276.trn

LS 23 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrole-3-propanoic acid, 5-(formyl-14C)-2,4-dimethyl- (9CI)
 MF C10 H13 N O3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

Page 5

=> 15

L6 23 L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.45	28.30

FILE 'CAPLUS' ENTERED AT 11:43:55 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007 (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 15

L7 18073 L5

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.47	28.77

FILE 'REGISTRY' ENTERED AT 11:44:36 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1
DICTIONARY FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

10523276.trn


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> d 15

LS ANSWER 1 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-89-3 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, 5-((formyl-14C)-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C15 H23 N3 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Page 8

=> d 15 2

10523276.trn

LS ANSWER 2 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-88-2 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-propanoic acid, 2-(formyl-14C)-5-methyl- (9CI) (CA INDEX
NAME)
MF C9 H11 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Page 10

=> d 15 3

10523276.trn

LS ANSWER 3 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-87-1 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-(formyl-14C)-2,4-
 dimethyl- (9CI) (CA INDEX NAME)
 MF C14 H23 N3 O2
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Page 12

=> d 15 4

LS ANSWER 4 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
RN 656253-86-0 REGISTRY
ED Entered STN: 01 Mar 2004
CN 1H-Pyrrole-3-carboxylic acid, 5-(formyl-14C)-2,4-dimethyl- (9CI) (CA
INDEX NAME)
MF C8 H9 N O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Page 14

=> d 15 5

10523276.trn

L5 ANSWER 5 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-85-9 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 5-(formyl-14C)-2,4-dimethyl- (9CI) (CA)
 INDEX
 NAME)
 MF C10 H13 N O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Page 16

=> d 15 6-23


10523276.trn

L5 ANSWER 6 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-84-8 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-2-carboxaldehyde-14C, 3,5-dimethyl- (9CI) (CA INDEX NAME)
 MF C7 H9 N O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 7 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-83-7 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 MF C22 H27 F N4 O2
 SR CA
 LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L5 ANSWER 8 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-82-6 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 MF C18 H18 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 9 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-81-5 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H27 F N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.
 Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 10 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-80-4 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-5-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C17 H16 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 11 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-79-1 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C22 H27 F N4 O2
 SR CA
 LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL


Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-78-0 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H18 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L5 ANSWER 13 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-77-9 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene-14C]-1,3-dihydro- (9CI) (CA INDEX NAME)
 MF C15 H14 N2 O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 14 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 452105-36-1 REGISTRY
 ED Entered STN: 17 Sep 2002
 CN 4-Morpholineethanol, n-(aminomethyl)-, (αS)- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN (2S)-1-Amino-3-(morpholin-4-yl)propan-2-ol
 FS STEREOSEARCH
 MF C7 H16 N2 O2
 SR CA
 LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPAT2, USPATFULL


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


6 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L5 ANSWER 15 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 61853-17-6 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN Formamide-14C, N,N-dimethyl- (6CI, 9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Formamide-14C, N,N-dimethyl- (7CI)
 MF C3 H7 N O
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHEM, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)



12 REFERENCES IN FILE CA (1907 TO DATE)
 12 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L5 ANSWER 16 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 60390-32-1 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Pyrrole-3-propanoic acid, 5-methyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pyrrole-3-propionic acid, 5-methyl- (6CI)
 MF C8 H11 N O2
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
 7 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L5 ANSWER 17 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 56341-41-4 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro- (CA INDEX NAME)
 OTHER NAMES:
 CN 5-Fluoro-1,3-dihydro-2H-indol-2-one
 CN 5-Fluoro-1,3-dihydroindol-2-one
 CN 5-Fluoro-2,3-dihydro-2-oxoindole
 CN 5-Fluoro-2-oxindole
 CN 5-Fluoro-2-oxoindoline
 CN 5-Fluorooxindole
 MF C8 H6 F N O
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM, IFICDB, IFIPAT, IFIUDS, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

86 REFERENCES IN FILE CA (1907 TO DATE)
 86 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L5 ANSWER 18 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 54474-50-9 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Pyrrole-3-propionic acid, 2,4-dimethyl- (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pyrrole-3-propionic acid, 2,4-dimethyl- (6CI, 7CI)
 OTHER NAMES:
 CN 3-(2,4-Dimethyl-1H-pyrrol-3-yl)propionic acid
 MF C9 H13 N O2
 CI COM
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CSCHM,
 TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1907 TO DATE)
 21 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 19 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 2199-51-1 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Pyrrole-3-carboxylic acid, 2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pyrrole-3-carboxylic acid, 2,4-dimethyl-, ethyl ester (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN 2,4-Dimethyl-1H-pyrrole-3-carboxylic acid ethyl ester
 CN 2,4-Dimethyl-3-(ethoxycarbonyl)pyrrole
 CN 2,4-Dimethyl-3-carboxypyrrole
 CN 3-(Ethoxycarbonyl)-2,4-dimethylpyrrole
 CN Ethyl 2,4-dimethylpyrrole-3-carboxylate
 CN NSC 13425
 MF C9 H13 N O2
 CI COM
 LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,
 CHEMINFORMRX, CSCHM, IFICDB, IFIPAT, IFIUDB, SPECINFO, TOXCENTER,
 USPAT2, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

106 REFERENCES IN FILE CA (1907 TO DATE)
 106 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 20 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 625-82-1 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Pyrrole, 2,4-dimethyl- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Pyrrole, 2,4-dimethyl- (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN 2,4-Dimethyl-1H-pyrrole
 CN 2,4-Dimethylpyrrole
 CN NSC 81347
 MF C6 H9 N
 CI COM
 LC STN Files: ANABSTR, BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CSCHM, DETHERM*, IFICDB, IFIPAT, IFIUDB,
 NAPRALERT, SCISEARCH, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

281 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 282 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 21 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 120-72-9 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Indole (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Indole (8CI)
 OTHER NAMES:
 CN 1-Azaindene
 CN 1-Benzazole
 CN 2,3-Benzopyrrole
 CN Benzol[b]pyrrole
 CN Ketole
 CN NSC 1964
 MF C8 H7 N
 CI COM, RPS
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS,
 BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX,
 CHEMLIST, CIN, CSCHM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT,
 ENCOMPLIT2, ENCOMPAT, ENCOMPAT2, GHELIN*, HSDB*, IFICDB, IFIPAT,
 IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, PS,
 RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13380 REFERENCES IN FILE CA (1907 TO DATE)
 2139 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 13429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)


L5 ANSWER 22 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 108-00-9 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1,2-Ethanediamine, N1,N1-dimethyl- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 1,2-Ethanediamine, N,N-dimethyl- (9CI)
 CN Ethylenediamine, N,N-dimethyl- (6CI, 7CI, 8CI)
 OTHER NAMES:
 CN (2-Aminoethyl)dimethylamine
 CN β -(Dimethylamino)ethylamine
 CN 1-Amino-2-(dimethylamino)ethane
 CN 2-(Dimethylamino)ethanamine
 CN 2-(Dimethylamino)ethylamine
 CN 2-(N,N-Dimethylamino)ethanamine
 CN 2-(N,N-Dimethylamino)ethylamine
 CN N,N-Dimethyl-1,2-diaminoethane
 CN N,N-Dimethyl-1,2-ethanediamine
 CN N,N-Dimethyl-1,2-ethylenediamine
 CN N,N-Dimethylethanediamine
 CN N,N-Dimethylethylenediamine
 CN N-Methyl-1,2-ethanediamine
 CN N-(2-Aminoethyl)-N,N-dimethylamine
 CN NSC 24506
 CN unsym-Dimethylethylenediamine
 MF C4 H12 N2
 CI COM
 LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS,
 CHEMINFORMRX, CHEMLIST, CSCHM, GMELIN*, IFICDB, IFIPAT, IFIUDB,
 MSDS-OHS, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2,
 USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS*, NDSL*, TSCA*
 (**Enter CHEMLIST File for up-to-date regulatory information)

Me₂N-CH₂-CH₂-NH₂

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3376 REFERENCES IN FILE CA (1907 TO DATE)
 235 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 3383 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L5 ANSWER 23 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 59-48-3 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2H-Indol-2-one, 1,3-dihydro- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2-Indolinone (7CI, 8CI)
 CN Oxindole (6CI)
 OTHER NAMES:
 CN 1,3-Dihydro-2H-indol-2-one
 CN 1,3-Dihydroindol-2-one
 CN 2-Indolone
 CN 2-Oxindole
 CN 2-Oxo-2,3-dihydroindole
 CN 2-Oxoindole
 CN 2-Oxoindoline
 CN Indol-2(3H)-one
 CN Indoline-2-one
 CN NSC 274863
 CN Oxindol
 MF C8 H7 N O
 CI COM
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO,
 CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN,
 CSCHM, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, PROMT,
 RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS*
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1092 REFERENCES IN FILE CA (1907 TO DATE)
 96 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1096 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d 15 12 /ide


' ' MUST END IN '/Q', '/A', '/L', '/S' OR '/B'

The saved name for a query (or structure or screen set) must end with '/Q'. The saved name for an answer set must end with '/A'. The saved name for an L# list must end with '/L'. SDI request names must end with '/S'. To see a list of all saved query, answer set,, and L# list names for this loginid, enter "DISPLAY SAVED" at an arrow prompt (=>). Enter "DISPLAY SAVED/S" to see a list of SDI request names. Enter "DISPLAY SAVED/B" to see a list of BATCH search requests.

=> d 15 12 ide

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-78-0 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H18 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Page 24

=> d 15 12 all


10523276.trn

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-78-0 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H18 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL
 DT.CA Caplus document type: Patent
 RL.P Roles from patents: PREP (Preparation)

Ring System Data

Elemental	Elemental	Size of	Ring System	Ring	RID
EA	ES	SZ	RF	RID	Count
C4N	INC4	15	IC4N	116.136.9	11
C4N-C6	INC4-C6	15-6	IC8N	1333.151.56	11

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)



REFERENCE 1

AN 140:163705 CA
 TI Process for preparation of isotopically labeled indolinone derivatives
 IN Giribone, Danilo; Pignatti, Alberto; Fontana, Erminia
 PA Pharmacia Italia S.P.A., Italy
 SO PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K051-04
 ICS C07D403-06: C07D403-14; C07D471-04
 CC 27-11 (Heterocyclic Compounds (One Hetero Atom))
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012776	A1	20040212	WO 2003-EP50340	20030728

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN (Continued)
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003262544 A1 20040223 AU 2003-262544 20030728
 EP 1542734 A1 20050622 EP 2003-766410 20030728
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, HK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006515564 T 20060601 JP 2004-525429 20030728
 US 2006166982 A1 20060727 US 2005-523276 20050919
 PRA1 EP 2002-78164 20020801
 WO 2003-EP50340 20030728



AB This invention pertains to a method for producing isotopically labeled [14C] indolinone deriva. with general formula of I [wherein R = alkyl, alkoxy, or halo; R1 = (un)substituted alkyl or CONH2; m = 0-4; n = 0-3]
 or pharmaceutically acceptable salts. For example, H14CONMe2 was reacted with 2,4-dimethylpyrrole in diphosphoryl chloride to give 3,5-dimethyl-1H-pyrrole-2-[14C]carboxaldehyde (49%). The above aldehyde was reacted with oxindole in EtOH in the presence of pyrrolidine to afford II (54%).
 ST isotopically labeling pyrrolyl indolinone prep
 IT Exchange reaction
 (preparation of isotopically labeled indolinone deriva.)
 IT 656253-84-8P 656253-85-9P 656253-86-0P 656253-87-1P 656253-88-2P 656253-89-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 IT 59-48-3, Oxindole 108-00-9, N,N-Dimethylethane-1,2-diamine 625-82-1, 2,4-Dimethylpyrrole 2199-51-1, 2,4-Dimethyl-1H-pyrrole-3-carboxylic acid
 ethyl ester 54474-50-9 56341-41-4 60390-32-1 61853-17-6 452105-36-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of isotopically labeled indolinone deriva.)

L5 ANSWER 12 OF 23 REGISTRY COPYRIGHT 2007 ACS on STN (Continued)
 IT 120-72-9DP, Indole, isotopically labeled deriva. 656253-77-9P
 656253-78-0P 656253-79-1P 656253-80-4P 656253-81-5P 656253-82-6P 656253-83-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of isotopically labeled indolinone deriva.)

=> 15 Nc4-C6/ES
MISSING OPERATOR

=> 15 and Nc4-C6/ES
1115147 NC4-C6/ES
L8 10 L5 AND NC4-C6/ES

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	59.82	88.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.73	-0.73

FILE 'CAPLUS' ENTERED AT 11:48:11 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007 (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 18
L9 14388 L8

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.47	89.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.73

FILE 'CAPLUS' ENTERED AT 11:48:20 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007 (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> l8

L10 14388 L8

=> l5 and Nc4-C6/ES

'ES' IS NOT A VALID FIELD CODE

18073 L5

0 NC4-C6/ES

L11 0 L5 AND NC4-C6/ES

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.47

89.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-0.73

FILE 'REGISTRY' ENTERED AT 11:48:38 ON 25 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

DICTIONARY FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>


=> l5 and Nc4-C6/ES

1115147 NC4-C6/ES

L12 10 L5 AND NC4-C6/ES


=> d 1-10

L12 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-83-7 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, N-[(2-(diethylamino)ethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 MF C22 H27 F N4 O2
 SR CA
 LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L12 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-82-6 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 MF C18 H18 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-81-5 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H27 F N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.
 Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-80-4 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-[1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-5-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C17 H16 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-79-1 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C22 H27 F N4 O2
 SR CA
 LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL


Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L12 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-78-0 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C18 H18 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.




1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-77-9 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene-14C]-1,3-dihydro- (9CI) (CA INDEX NAME)
 MF C15 H14 N2 O
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L12 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 56341-41-4 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2H-Indol-2-one, 5-fluoro-1,3-dihydro- (CA INDEX NAME)
 OTHER NAMES:
 CN 5-Fluoro-1,3-dihydro-2H-indol-2-one
 CN 5-Fluoro-1,3-dihydroindol-2-one
 CN 5-Fluoro-2,3-dihydro-2-oxoindole
 CN 5-Fluoro-2-oxindole
 CN 5-Fluoro-2-oxoindoline
 CN 5-Fluorooxindole
 MF C8 H6 F N O
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEN, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

86 REFERENCES IN FILE CA (1907 TO DATE)
 86 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L12 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 120-72-9 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 1H-Indole (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN Indole (8CI)
 OTHER NAMES:
 CN 1-Azaindene
 CN 1-Benzazole
 CN 2,3-Benzopyrrole
 CN Benzo[b]pyrrole
 CN Ketole
 CN NSC 1964
 MF C8 H7 N
 CI COM, RPS
 LC STN files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, ENCOMPLIT, ENCOMPLIT2, ENCOMPPAT, ENCOMPPAT2, GMEIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, PIRA, PROMT, PS, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, TULSA, ULIDAT, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: DSL**, EINECS**, TSCA**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

13380 REFERENCES IN FILE CA (1907 TO DATE)
 2139 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 13429 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 6 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L12 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 59-48-3 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN 2H-Indol-2-one, 1,3-dihydro- (CA INDEX NAME)
 OTHER CA INDEX NAMES:
 CN 2-Indolinone (7CI, 8CI)
 CN Oxindole (6CI)
 OTHER NAMES:
 CN 1,3-Dihydro-2H-indol-2-one
 CN 1,3-Dihydroindol-2-one
 CN 2-Indolone
 CN 2-Oxindole
 CN 2-Oxo-2,3-dihydroindole
 CN 2-Oxoindole
 CN 2-Oxoindoline
 CN Indol-2(3H)-one
 CN Indoline-2-one
 CN NSC 274863
 CN Oxindol
 MF C8 H7 N O
 CI COM
 LC STN files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCEM, EMBASE, IFICDB, IFIPAT, IFIUDB, MEDLINE, NAPRALERT, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1092 REFERENCES IN FILE CA (1907 TO DATE)
 96 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 1096 REFERENCES IN FILE CAPLUS (1907 TO DATE)
 27 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

Page 32

=> 15 and Nc4-C6/ES and NC4/es


1115147 NC4-C6/ES

1664117 NC4/ES

L13 7 L5 AND NC4-C6/ES AND NC4/ES


=> d 1-7

L13 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-83-7 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, N-[(2-(diethylamino)ethyl)-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 MF C22 H27 F N4 O2
 SR CA
 LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L13 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-82-6 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 MF C18 H18 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-81-5 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C23 H27 F N4 O4
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.
 Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 656253-80-4 REGISTRY
 ED Entered STN: 01 Mar 2004
 CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-5-methyl- (9CI) (CA INDEX NAME)
 FS STEREOSEARCH
 MF C17 H16 N2 O3
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN

RN 656253-79-1 REGISTRY

ED Entered STN: 01 Mar 2004

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C22 H27 F N4 O2

SR CA

LC STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN

RN 656253-78-0 REGISTRY

ED Entered STN: 01 Mar 2004

CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C18 H18 N2 O3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L13 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2007 ACS on STN

RN 656253-77-9 REGISTRY

ED Entered STN: 01 Mar 2004


CN 2H-Indol-2-one,

3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene-14C]-1,3-dihydro- (9CI) (CA INDEX NAME)

MF C15 H14 N2 O

SR CA

LC STN Files: CA, CAPLUS, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
48.90	138.43

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.73

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 11:49:39 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2007 VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007 (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> l13
L14 1 L13

=> d ibib abs hitstr

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2004:120755 CAPLUS
 DOCUMENT NUMBER: 140:163705
 TITLE: Process for preparation of isotopically labeled indolinone derivatives
 INVENTOR(S): Giribone, Danilo; Pignatti, Alberto; Fontana, Erminia
 PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012776	A1	20040212	WO 2003-EP50340	20030728
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2003262544 A1 20040223 AU 2003-262544 20030728 EP 1542734 A1 20050622 EP 2003-766410 20030728 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK JP 2006515564 T 20060601 JP 2004-525429 20030728 US 2006166982 A1 20060727 US 2005-523276 20050919 EP 2002-78164 A 20020801				
PRIORITY APPLN. INFO.: WO 2003-EP50340 W 20030728				


OTHER SOURCE(S): MARPAT 140:163705
 GI



AB This invention pertains to a method for producing isotopically labeled [14C] indolinone derivs. with general formula of I [wherein R = alkyl,


L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 alkoxy, or halo; R1 = (un)substituted alkyl or CONH2; m = 0-4; n = 0-3]
 or pharmaceutically acceptable salts. For example, H14CONMe2 was reacted with 2,4-dimethylpyrrole in diphosphoryl chloride to give 3,5-dimethyl-1H-pyrrole-2-[14C]carboxaldehyde (49%). The above aldehyde was reacted with oxindole in EtOH in the presence of pyrrolidine to afford

II (54%).
 IT 656253-77-9P 656253-78-0P 656253-79-1P
 656253-80-4P 656253-81-5P 656253-82-6P
 656253-83-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Preparation of isotopically labeled indolinone derivs.)
 RN 656253-77-9 CAPLUS
 CN 2H-Indol-2-one,
 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene-14C]-1,3-dihydro-
 (9CI) (CA INDEX NAME)



RN 656253-78-0 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 656253-79-1 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 656253-80-4 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 2-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 656253-81-5 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(2)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-N-[(2S)-2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 656253-82-6 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 656253-83-7 CAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl-14C]-2,4-dimethyl- (9CI) (CA INDEX NAME)



=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

8.09

146.52

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.78

-1.51

FILE 'REGISTRY' ENTERED AT 11:53:19 ON 25 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

DICTIONARY FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10523276\Struc 1.str



chain nodes :

1 4 5 6

ring nodes :

2 3 7 8 9 10 11 12 13 14 15 16 17 18

chain bonds :

1-9 4-17 5-15 5-7 6-16

ring bonds :

2-9 2-10 3-15 3-17 7-8 7-9 8-10 8-11 10-12 11-13 12-14 13-14 15-16
16-18 17-18

exact/norm bonds :

1-9 2-9 2-10 3-15 3-17 7-8 7-9 15-16 16-18 17-18

exact bonds :

4-17 5-15 5-7 6-16

normalized bonds :

8-10 8-11 10-12 11-13 12-14 13-14

Match level :


1:CLASS 2:Atom 3:Atom 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom

L15 STRUCTURE UPLOADED

=> d

L15 HAS NO ANSWERS

L15 STR



Structure attributes must be viewed using STN Express query preparation.

=> l15

SAMPLE SEARCH INITIATED 11:53:34 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 221 TO ITERATE

100.0% PROCESSED 221 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 3529 TO 5311

PROJECTED ANSWERS: 1081 TO 2159

L16 50 SEA SSS SAM L15

=> l15 exa

SAMPLE SEARCH INITIATED 11:53:38 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L17 0 SEA EXA SAM L15


Page 39

=> d scan
L17 HAS NO ANSWERS

=> d scan 116

L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Heptanoic acid, 7-[[[5-[(Z)-(4,5-difluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3,5-dihydroxy-
 (3R,5R)-
 MF C23 H25 F2 N3 O6
 CI COM

Absolute stereochemistry.
 Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4


L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrole-2-carboxylic acid, 1-[4-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-3-methoxy-1-oxobutyl]-2,5-dihydro-
 MF C26 H27 F N4 O6

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1H-Pyrrole-3-propanamide,
 5-[[[1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-
 N,2,4-trimethyl-N-(7-(methylamino)heptyl)- (9CI)
 MF C27 H38 N4 O2
 CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN L-Threonine,
 N-[2-ethoxy-4-[[[5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]-1-oxobutyl]-
 MF C26 H31 F N4 O7


Absolute stereochemistry.
 Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2H-Indol-2-one, 3-[[4-[(cyclopropylmethylamino)methyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)methylene]-1,3-dihydro-5-[[[2-[2-(4-
 morpholinylethoxy)phenyl]methyl]sulfonyl]-, (3Z)- (9CI)
 MF C33 H40 N4 O5 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file guide

'GUIDE' IS NOT A VALID FILE NAME

SESSION CONTINUES IN FILE 'REGISTRY'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.25	148.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.51

FILE 'STNGUIDE' ENTERED AT 11:56:33 ON 25 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: May 18, 2007 (20070518/UP).

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.24	149.01
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.51

FILE 'REGISTRY' ENTERED AT 11:58:44 ON 25 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

DICTIONARY FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10523276\Struc 7.str



chain nodes :

1 4 5 6 7 8 9 10 11 12 13 14

ring nodes :

2 3 15 16 17 18 19 20 21 22 23 24 25 26

chain bonds :

1-17 4-26 5-23 5-15 6-21 7-24 8-25 8-9 8-14 9-10 10-11 11-12 12-13

ring bonds :

2-17 2-18 3-23 3-26 15-16 15-17 16-18 16-19 18-20 19-21 20-22 21-22
23-24 24-25 25-26

exact/norm bonds :

1-17 2-17 2-18 3-23 3-26 8-9 8-14 15-16 15-17 23-24 24-25 25-26

exact bonds :

4-26 5-23 5-15 6-21 7-24 8-25 9-10 10-11 11-12 12-13

normalized bonds :

16-18 16-19 18-20 19-21 20-22 21-22

Match level :

1:CLASS 2:Atom 3:Atom 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS


10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom

18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom

L18 STRUCTURE UPLOADED

=>

Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 2.str



chain nodes :

1 3 4 5 6 8 21 22

ring nodes :

2 7 9 10 11 12 13 14 15 16 17 18 19 20

chain bonds :

1-18 3-11 4-22 5-20 6-17 6-8 6-9 19-21 21-22

ring bonds :

10523276.trn

2-11 2-12 7-17 7-20 9-10 9-11 10-12 10-13 12-14 13-15 14-16 15-16 17-18
 18-19 19-20
 exact/norm bonds :
 2-11 2-12 3-11 7-17 7-20 9-10 9-11 17-18 18-19 19-20
 exact bonds :
 1-18 4-22 5-20 6-17 6-8 6-9 19-21 21-22
 normalized bonds :
 10-12 10-13 12-14 13-15 14-16 15-16


Match level :

1:CLASS 2:Atom 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:Atom 8:CLASS 9:Atom
 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
 19:Atom 20:Atom 21:CLASS 22:CLASS

L19 STRUCTURE UPLOADED

=>

Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 3.str



chain nodes :

1 2 4 5 6 7 8 9 10 12 25 26 27

ring nodes :

3 11 13 14 15 16 17 18 19 20 21 22 23 24

chain bonds :

1-25 2-22 4-15 5-6 5-27 7-25 7-26 8-24 9-19 10-21 10-12 10-13 23-25
 26-27

ring bonds :

3-15 3-16 11-21 11-24 13-14 13-15 14-16 14-17 16-18 17-19 18-20 19-20
 21-22 22-23 23-24

exact/norm bonds :

1-25 3-15 3-16 4-15 5-27 7-25 7-26 11-21 11-24 13-14 13-15 21-22 22-23
 23-24

exact bonds :

2-22 5-6 8-24 9-19 10-21 10-12 10-13 23-25 26-27

normalized bonds :

14-16 14-17 16-18 17-19 18-20 19-20



Match level :

1:CLASS 2:CLASS 3:Atom 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:CLASS 11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:CLASS 26:CLASS 27:CLASS

L20 STRUCTURE UPLOADED

=>

Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 4.str



chain nodes :

1 3 4 5 7 20 21

ring nodes :

2 6 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

1-21 3-10 4-19 5-16 5-7 5-8 17-20 20-21

ring bonds :

2-10 2-11 6-16 6-19 8-9 8-10 9-11 9-12 11-13 12-14 13-15 14-15 16-17 17-18 18-19

exact/norm bonds :

2-10 2-11 3-10 6-16 6-19 8-9 8-10 16-17 17-18 18-19

exact bonds :

1-21 4-19 5-16 5-7 5-8 17-20 20-21

normalized bonds :

9-11 9-12 11-13 12-14 13-15 14-15


Match level :

1:CLASS 2:Atom 3:CLASS 4:CLASS 5:CLASS 6:Atom 7:CLASS 8:Atom 9:Atom
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:CLASS 21:CLASS

L21 STRUCTURE UPLOADED

=>

Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 5.str



chain nodes :

```

1  2  4  5  7  9 10 11 13 26 27 28 29
ring nodes :
3  6  8 12 14 15 16 17 18 19 20 21 22 23 24 25 30 31 32 33
chain bonds :
1-26 2-23 4-16 5-26 5-27 6-29 7-28 9-25 10-20 11-22 11-13 11-14 24-26
27-28 28-29
ring bonds :
3-16 3-17 6-30 6-31 8-32 8-33 12-22 12-25 14-15 14-16 15-17 15-18 17-19
18-20 19-21 20-21 22-23 23-24 24-25 30-32 31-33
exact/norm bonds :
1-26 3-16 3-17 4-16 5-26 5-27 6-29 6-30 6-31 7-28 8-32 8-33 12-22
12-25 14-15 14-16 22-23 23-24 24-25 30-32 31-33
exact bonds :
2-23 9-25 10-20 11-22 11-13 11-14 24-26 27-28 28-29
normalized bonds :
15-17 15-18 17-19 18-20 19-21 20-21

```

Match level :

```

1:CLASS 2:CLASS 3:Atom 4:CLASS 5:CLASS 6:Atom 7:CLASS 8:Atom 9:CLASS
10:CLASS 11:CLASS 12:Atom 13:CLASS 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:Atom 31:Atom 32:Atom 33:Atom

```

Stereo Bonds:

28-7 (Single Wedge).

Stereo Chiral Centers:

28 (Parity=Don't Care)


Stereo RSS Sets:

Type=Relative (Default). 1 Nodes= 28

L22 STRUCTURE UPLOADED

=>

Uploading c:\Program Files\Stnexp\Queries\10523276\Struc 6.str



```

chain nodes :
1  4  5  6  7  8  9
ring nodes :
2  3 10 11 12 13 14 15 16 17 18 19 20 21
chain bonds :
1-12 4-21 5-18 5-10 6-19 7-20 7-8 8-9
ring bonds :
2-12 2-13 3-18 3-21 10-11 10-12 11-13 11-14 13-15 14-16 15-17 16-17
18-19 19-20 20-21

```

exact/norm bonds :
 1-12 2-12 2-13 3-18 3-21 10-11 10-12 18-19 19-20 20-21
 exact bonds :
 4-21 5-18 5-10 6-19 7-20 7-8 8-9
 normalized bonds :
 11-13 11-14 13-15 14-16 15-17 16-17

Match level :
 1:CLASS 2:Atom 3:Atom 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom
 19:Atom 20:Atom 21:Atom

L23 STRUCTURE UPLOADED

=> 118 exa
 SAMPLE SEARCH INITIATED 11:59:50 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 0 TO 0
 PROJECTED ANSWERS: 0 TO 0

L24 0 SEA EXA SAM L18

=> 119 exa
 SAMPLE SEARCH INITIATED 11:59:56 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 0 TO 0
 PROJECTED ANSWERS: 0 TO 0

L25 0 SEA EXA SAM L19

=> 120 exa
 SAMPLE SEARCH INITIATED 12:00:01 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 0 TO 0
 PROJECTED ANSWERS: 0 TO 0

L26 0 SEA EXA SAM L20

=> l21 exa

SAMPLE SEARCH INITIATED 12:00:11 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L27 0 SEA EXA SAM L21

=> l22 exa

SAMPLE SEARCH INITIATED 12:00:16 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 1 TO 80
PROJECTED ANSWERS: 0 TO 0

L28 0 SEA EXA SAM L22

=> l23 exa

SAMPLE SEARCH INITIATED 12:00:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L29 0 SEA EXA SAM L23

=> d his

(FILE 'HOME' ENTERED AT 11:40:42 ON 25 MAY 2007)

FILE 'CAPLUS' ENTERED AT 11:40:51 ON 25 MAY 2007
E US2005-523276/AP,PRN 25

L1 1 S E3

FILE 'REGISTRY' ENTERED AT 11:42:15 ON 25 MAY 2007

FILE 'CAPLUS' ENTERED AT 11:42:23 ON 25 MAY 2007

L2 TRA L1 1- TI : 6 TERMS

L3 FILE 'REGISTRY' ENTERED AT 11:42:24 ON 25 MAY 2007
0 SEA L2/RN

L4 FILE 'CAPLUS' ENTERED AT 11:43:38 ON 25 MAY 2007
TRA L1 1- RN : 23 TERMS

L5 FILE 'REGISTRY' ENTERED AT 11:43:38 ON 25 MAY 2007
23 SEA L4
L6 23 L5

L7 FILE 'CAPLUS' ENTERED AT 11:43:55 ON 25 MAY 2007
18073 L5

L8 FILE 'REGISTRY' ENTERED AT 11:44:36 ON 25 MAY 2007
10 L5 AND NC4-C6/ES

L9 FILE 'CAPLUS' ENTERED AT 11:48:11 ON 25 MAY 2007
14388 L8

L10 FILE 'CAPLUS' ENTERED AT 11:48:20 ON 25 MAY 2007
14388 L8
L11 0 L5 AND NC4-C6/ES

L12 FILE 'REGISTRY' ENTERED AT 11:48:38 ON 25 MAY 2007
10 L5 AND NC4-C6/ES
L13 7 L5 AND NC4-C6/ES AND NC4/ES


L14 FILE 'CAPLUS' ENTERED AT 11:49:39 ON 25 MAY 2007
1 L13

L15 FILE 'REGISTRY' ENTERED AT 11:53:19 ON 25 MAY 2007
STRUCTURE UPLOADED
L16 50 L15
L17 0 L15 EXA

FILE 'STNGUIDE' ENTERED AT 11:56:33 ON 25 MAY 2007

L18 FILE 'REGISTRY' ENTERED AT 11:58:44 ON 25 MAY 2007
STRUCTURE UPLOADED
L19 STRUCTURE UPLOADED
L20 STRUCTURE UPLOADED
L21 STRUCTURE UPLOADED
L22 STRUCTURE UPLOADED
L23 STRUCTURE UPLOADED
L24 0 L18 EXA
L25 0 L19 EXA
L26 0 L20 EXA
L27 0 L21 EXA
L28 0 L22 EXA
L29 0 L23 EXA



=> d l15
L15 HAS NO ANSWERS
L15 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10523276\Struc 8.str



chain nodes :

1 4

ring nodes :

2 3 5 6 7 8 9 10 11 12 13 14 15 16

chain bonds :

1-7 4-13 4-5

ring bonds :

2-7 2-8 3-13 3-15 5-6 5-7 6-8 6-9 8-10 9-11 10-12 11-12 13-14 14-16 15-16

exact/norm bonds :

1-7 2-7 2-8 3-13 3-15 5-6 5-7 13-14 14-16 15-16

exact bonds :

4-13 4-5

normalized bonds :

6-8 6-9 8-10 9-11 10-12 11-12

Match level :


1:CLASS 2:Atom 3:Atom 4:CLASS 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom

L30 STRUCTURE UPLOADED

=> d

L30 HAS NO ANSWERS

L30 STR



Structure attributes must be viewed using STN Express query preparation.

=> 130

SAMPLE SEARCH INITIATED 12:02:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 605 TO ITERATE

100.0% PROCESSED 605 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 10625 TO 13575
PROJECTED ANSWERS: 2654 TO 4226

L31 50 SEA SSS SAM L30

=> 130 full

FULL SEARCH INITIATED 12:02:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12244 TO ITERATE

100.0% PROCESSED 12244 ITERATIONS 3608 ANSWERS
SEARCH TIME: 00.00.01

L32 3608 SEA SSS FUL L30

=> file medline caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	174.80	323.81
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.51

FILE 'MEDLINE' ENTERED AT 12:02:45 ON 25 MAY 2007

FILE 'CAPLUS' ENTERED AT 12:02:45 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> 132

L33 760 L32

=> dup rem 132

DUPLICATE IS NOT AVAILABLE IN 'REGISTRY'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	73.02	396.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.51

FILE 'REGISTRY' ENTERED AT 12:02:54 ON 23 MAY 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1
 DICTIONARY FILE UPDATES: 24 MAY 2007 HIGHEST RN 935837-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

PROCESSING COMPLETED FOR L32
 L34 3608 DUP REM L32 (0 DUPLICATES REMOVED)

Page 54

=> file medline caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.45	397.28

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-1.51

CA SUBSCRIBER PRICE

FILE 'MEDLINE' ENTERED AT 12:03:14 ON 25 MAY 2007

FILE 'CAPLUS' ENTERED AT 12:03:14 ON 25 MAY 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


=> dup rem l33

PROCESSING COMPLETED FOR L33

L35 723 DUP REM L33 (37 DUPLICATES REMOVED)


=> d ibib abs hitstr 701-723

L35 ANSWER 701 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:810602 CAPLUS
 DOCUMENT NUMBER: 132:160709
 TITLE: Antiangiogenic agents
 AUTHOR(S): Klohs, Wayne D.; Hamby, James M.
 CORPORATE SOURCE: Department of Drug Development, Parke-Davis
 Pharmaceutical Research, Warner-Lambert Company, Ann
 Arbor, MI, 48105, USA
 SOURCE: Current Opinion in Biotechnology (1999), 10(6),
 544-549
 CODEN: CUOBE3; ISSN: 0958-1669
 PUBLISHER: Current Biology Publications
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English
 AB A review with 32 refs. A greater understanding of the complex process of
 tumor-induced angiogenesis, coupled with the notion that tumors require a
 blood supply to both grow and metastasize, has fueled the search for
 agents that block or disrupt the angiogenic process. Because normal
 vascular endothelial cells (ECs) turn over so slowly, conventional wisdom
 suggests that an antiangiogenic approach to cancer therapy should offer
 improved efficacy and reduced toxicity, without the potential for drug
 resistance. Numerous reports have identified small mols. or antibodies
 that can interfere with one or more key steps in EC signaling, migration
 or differentiation. Three new compds., ZD4190, SU6668 and PD 0173074,
 have been reported during the past year to have significant and selective
 antiangiogenic activity, as well as antitumor activity.
 IT 252916-29-3, SU6668
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (antiangiogenic agents for treatment of cancer)
 RN 252916-29-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
 ylidene)methyl]-2,4-dimethyl- (CA INDEX NAME)




REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L35 ANSWER 702 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L35 ANSWER 702 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:728476 CAPLUS
 DOCUMENT NUMBER: 132:58536
 TITLE: Identification of geometric isomer of compound
 3-[(3,5-dimethyl-2-pyrrolylmethylene)-5-bromoindolone
 by using theoretical calculation and 1H NMR
 AUTHOR(S): Zheng, Zhibing; Hu, Yuandong; Cui, Guangyao; Xie,
 Yunde; Jiao, Kefang; Li, Song
 CORPORATE SOURCE: Inst. Pharmacol. Toxicol., Acad. Mil. Med. Sci.,
 Beijing, 100850, Peop. Rep. China
 SOURCE: Bopuxue Zazhi (1999), 16(5), 455-460
 CODEN: BOZAE2; ISSN: 1000-4556
 PUBLISHER: Zhongguo Kexueyuan Wuhu Wuli Yanjiusuo
 DOCUMENT TYPE: Journal
 LANGUAGE: Chinese
 AB The methods of MM2 and AM1 of MOPAC97 was used to calculate the mol.
 geometric isomers. The distance parameters of the atoms of the two configurations
 of the mol. were calculated, and the possible NOE effects were predicted
 according to the necessary condition of having NOE between atoms. The
 geometric configuration of the mol. was confirmed by contrasting the
 results of exptl. and predicted NOE effects.
 IT 194413-57-5 194413-58-6
 RL: ANT (Analyte); PRP (Properties); ANST (Analytical study)
 (identification of geometric isomer of compound 3-[(3,5-dimethyl-2-
 pyrrolylmethylene)-5-bromoindolone by using theor. calcn. and 1H NMR)
 RN 194413-57-5 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-,
 (3E)- (9CI) (CA INDEX NAME)



Double bond geometry as shown.
 RN 194413-58-6 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-,
 (3Z)- (CA INDEX NAME)

Double bond geometry as shown.

L35 ANSWER 703 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1999:65738 CAPLUS
 DOCUMENT NUMBER: 130:246450
 TITLE: SU5416 is a potent and selective inhibitor of the
 vascular endothelial growth factor receptor
 (Flk-1/KDR) that inhibits tyrosine kinase catalysis,
 tumor vascularization, and growth of multiple tumor
 types
 AUTHOR(S): Fong, T. Annie T.; Shawver, Laura K.; Sun, Li; Tang,
 Cho; App, Harald; Powell, T. Jeff; Kim, Young H.;
 Schreck, Randall; Wang, Xueyan; Risau, Werner;
 Ullrich, Axel; Hirth, K. Peter; McMahon, Gerald
 CORPORATE SOURCE: SUGEN, Inc., South San Francisco, CA, 94080, USA
 SOURCE: Cancer Research (1999), 59(11), 99-106
 CODEN: CNREAS; ISSN: 0008-5472
 PUBLISHER: AACR Subscription Office
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB SU5416, a novel synthetic compound, is a potent and selective inhibitor
 of
 the Flk-1/KDR receptor tyrosine kinase that is presently under evaluation
 in Phase I clin. studies for the treatment of human cancers. SU5416 was
 shown to inhibit vascular endothelial growth factor-dependent mitogenesis
 of human endothelial cells without inhibiting the growth of a variety of
 tumor cells in vitro. In contrast, systemic administration of SU5416 at
 nontoxic doses in mice resulted in inhibition of s.c. tumor growth of
 cells derived from various tissue origins. The antitumor effect of
 SU5416
 was accompanied by the appearance of pale white tumors that were resected
 from drug-treated animals, supporting the antiangiogenic property of this
 agent. These findings support that pharmacol. inhibition of the enzymic
 activity of the vascular endothelial growth factor receptor represents a
 novel strategy for limiting the growth of a wide variety of tumor types.
 IT 204005-46-9, SU 5416
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (SU5416: selective inhibitor of Flk-1/KDR receptor tyrosine kinase,
 tumor vascularization and growth)
 RN 204005-46-9 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
 (CA INDEX NAME)




REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L35 ANSWER 703 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L35 ANSWER 704 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:117816 CAPLUS
DOCUMENT NUMBER: 133:37825
TITLE: Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multifuorescence videomicroscopy
AUTHOR(S): Vajkoczy, Peter; Menger, Michael D.; Vollmar, Brigitte; Schilling, Lothar; Schmiedek, Peter; Hirth, K. Peter; Ullrich, Axel; Fong, T. Annie T.
CORPORATE SOURCE: Department of Neurosurgery, Klinikum Mannheim, University of Heidelberg, Mannheim, D-68167, Germany
SOURCE: Neoplasia (New York) (1999), 1(1), 31-41
CODEN: NEOPFL; ISSN: 1522-8002
PUBLISHER: Stockton Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Vascular endothelial growth factor (VEGF) plays a fundamental role in mediating tumor angiogenesis and tumor growth. The direct effect of SU5416, a novel small-mol. inhibitor of the Flk-1-mediated signal transduction pathway of VEGF, on tumor angiogenesis and microhemodynamics of an exptl. glioblastoma was investigated by intravital multifuorescence videomicroscopy. SU5416 treatment suppressed tumor growth. In parallel, SU5416 demonstrated a potent antiangiogenic activity, resulting in reduction of both the total and functional vascular d. of the tumor microvasculature, which indicates an impaired vascularization as well as perfusion failure in the treated tumors. This malperfusion was not compensated for by changes in vessel diameter or recruitment of nonperfused vessels. Analyses of the tumor microcirculation revealed microhemodynamic changes after angiogenesis blockade, such as a higher red cell velocity and blood flow in remnant tumor vessels than in controls. The results demonstrate that the novel antiangiogenic concept of targeting the tyrosine kinase of Flk-1/KDR by means of a small-mol. inhibitor represents an efficient strategy for controlling growth and progression of angiogenesis-dependent tumors.
IT 204005-46-9, SU 5416
RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified); BIOL (Biological study) (inhibition of glioblastoma growth, angiogenesis, and microcirculation by tyrosine kinase inhibitor SU5416)
RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)

L35 ANSWER 704 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:747592 CAPLUS
DOCUMENT NUMBER: 130:3771
TITLE: Preparation of 3-(hetero)arylmethylidene-2-indolinone derivatives as modulators of protein kinase activity for use in treating cancer.
INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Shawver, Laura Kay; Hirth, Klaus Peter
PATENT ASSIGNEE(S): Sugen, Inc., USA
SOURCE: PCT Int. Appl., 269 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9850356	A1	19981112	WO 1998-US9017	19980507
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2289102	A1	19981112	CA 1998-2289102	19980507
AU 9876842	A	19981127	AU 1998-76842	19980507
EP 984930	A1	20000315	EP 1998-924746	19980507
EP 984930	B1	20050406		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002511852	T	20020416	JP 1998-548319	19980507
AT 292623	T	20050415	AT 1998-924746	19980507
ES 2239393	T3	20050916	ES 1998-924746	19980507
US 6051593	A	20000418	US 1998-99721	19980619
US 6313158	B1	20011106	US 1998-100854	19980619
US 6133305	A	20001017	US 1998-161046	19980925
US 2001056094	A1	20011227	US 2000-482198	20000112
US 2001007033	A1	20010705	US 2000-516948	20000301
US 2002026053	A1	20020228	US 2001-916331	20010730
US 6506763	B2	20030114		
US 2002058661	A1	20020516	US 2001-948106	20010907
US 6696463	B2	20040224		
US 2002183370	A1	20021205	US 2001-29946	20011231
US 6579897	B2	20030617		
US 2004106630	A1	20040603	US 2003-725079	20031202
US 2004106618	A1	20040603	US 2003-725267	20031202
US 7189721	B2	20070313		
PRIORITY APPLN. INFO.:			US 1997-45838P	P 19970507
			US 1997-46868P	P 19970508
			US 1997-49324P	P 19970611
			US 1997-50412P	P 19970620
			US 1997-50413P	P 19970620


L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 US 1997-50977P P 19970620
 US 1997-59336P P 19970919
 US 1997-59381P P 19970919
 US 1997-59384P P 19970919
 US 1997-59544P P 19970919
 US 1997-59677P P 19970919
 US 1997-59971P P 19970925
 US 1997-60194P P 19970926
 US 1998-74621 A3 19980507
 WO 1998-US9017 W 19980507
 US 1998-100854 A3 19980619
 US 1998-99721 A1 19980619
 US 1998-161046 A3 19980925
 US 2000-482198 A3 20000112
 US 2000-516948 B1 20000301
 US 2001-819698 A3 20010329

OTHER SOURCE(S): MARPAT 130:3771
 GI




AB Title compds. (I; A1-A4 = C, N; when any of A1-A4 = N, then the corresponding R3-R6 = null; R1 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, trihalomethylcarbonyl, OH, CO2H, trihalomethylsulfonyl, etc.; R2 = H, alkyl, cycloalkyl, aryl, heteroaryl,

L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 heteroalicyclic, halo; R3-R6 = H, alkyl, trihalomethyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, OH, SH, alkoxy, aryloxy, amino, phosphonyl, guanidiny, NO2, halo, (isocyanato, etc.; R3R4 or R4R5 or R5R6 = cycloalkyl, aryl, heteroaryl, heteroalicyclic, OCH2O, OCH2CH2O; Q = specified (substituted) (hetero)aryl; Z = O, S),
 were
 prepd. Thus, 3-(4-imidazolylmethylidenyl)-4,6-dimethyl-2-indolinone inhibited CDK2 with IC50 = <0.78 μM.
 IT 15966-93-5 186611-30-3 186611-31-4
 186611-33-6 186611-34-7 186611-37-0
 215434-66-5 215536-85-9 215536-87-1
 215536-88-2 215536-91-7 215537-01-2
 215537-21-6 215537-24-9 215537-55-6
 215537-79-4 215543-92-3 215543-93-4
 215543-94-5 215543-95-6 215543-96-7
 215543-97-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses)
 (preparation of 3-(hetero)arylmethylidene-2-indolinone deriva. as modulators of protein kinase activity for use in treating cancer)
 RN 15966-93-5 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-30-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 186611-31-4 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-33-6 CAPLUS
 CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-37-0 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 215434-66-5 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-4-methyl-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 215536-85-9 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-4-methyl-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)




RN 215536-87-1 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215536-88-2 CAPLUS


L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215536-91-7 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(5,7-dibromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 215537-01-2 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-21-6 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-4-methyl-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)


L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 215543-92-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (CA INDEX NAME)



RN 215543-93-4 CAPLUS
 CN 2H-Indol-2-one, 3-[(5-acetyl-3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 215543-94-5 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 215543-95-6 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5,6-dimethoxy-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 215537-24-9 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-55-6 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 215537-79-4 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




L35 ANSWER 705 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 215543-96-7 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-[[4-(methoxycarbonyl)benzoyl]amino]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 215543-97-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L35 ANSWER 706 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1998:685118 CAPLUS
 DOCUMENT NUMBER: 129:310905
 TITLE: Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
 INVENTOR(S): Clary, Douglas
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9845708	A1	19981015	WO 1998-US6842	19980407
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9868876	A	19981030	AU 1998-68876	19980407
US 2002068361	A1	20020606	US 1998-57150	19980407
US 6235769	B1	20010522	US 1998-109883	19980702
PRIORITY APPLN. INFO.:			US 1997-43207P	P 19970408
			US 1997-51715P	P 19970703
			WO 1998-US6842	W 19980407


AB The invention relates to methods of evaluating the specific function of a receptor protein tyrosine kinase in cells by activating the receptor in a ligand-independent fashion. In addition, the invention includes methods of identifying compds. that modulate receptor protein tyrosine kinase function. The invention also relates to a method of preventing or treating an abnormal condition caused by an aberration in the function of the C-RET receptor, and specifically to the treatment and prevention of neurodegenerative disorders by administering a compound that modulates the function of the C-RET receptor.
 IT 204003-90-7 204003-91-8 204003-96-3
 204003-97-4
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases, and screening method)

L35 ANSWER 706 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L35 ANSWER 706 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 RN 204003-90-7 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-91-8 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-96-3 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 3-[[3,5-bis(1-methylethyl)-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-97-4 CAPLUS
 CN 1H-Indole-5-propanoic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)



L35 ANSWER 707 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1998:151222 CAPLUS
 DOCUMENT NUMBER: 128:164361
 TITLE: Crystal structures of a protein tyrosine kinase
 INVENTOR(S): Mohammadi, Moosa; Li, Sun; Liang, Congxin; Schllessinger, Joseph; Hubbard, Stevan R.; McMahon, Gerald; Tang, Peng C.
 PATENT ASSIGNEE(S): Sugen, Inc., USA; Mohammadi, Moosa; Li, Sun; Liang, Congxin; Schllessinger, Joseph; Hubbard, Stevan R.; McMahon, Gerald; Tang, Peng C.
 SOURCE: PCT Int. Appl., 493 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807835	A2	19980226	WO 1997-US14885	19970821
WO 9807835	A3	19981001		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5942428	A	19990824	US 1996-701191	19960821
CA 2263838	A1	19980226	CA 1997-2263838	19970821
AU 9741603	A	19980306	AU 1997-41603	19970821
EP 931152	A2	19990728	EP 1997-939534	19970821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001514484	T	20010911	JP 1998-511036	19970821
US 6682921	B1	20040127	US 2000-664526	20000918
US 2004185547	A1	20040923	US 2004-763418	20040126
PRIORITY APPLN. INFO.:			US 1996-701191	A 19960821
			US 1996-34168P	P 19961219
			WO 1997-US14885	W 19970821
			US 1998-188809	B1 19981109
			US 2000-664526	A3 20000918

OTHER SOURCE(S): MARPAT 128:164361
 AB The present invention relates to the 3-dimensional structures of a protein tyrosine kinase optionally complexed with one or more compds. Thus, a 310-amino acid fragment fibroblast growth factor receptor 1 (residues 456-765, FGFR1) was recombinantly prepared containing the amino acid substitutions Cys488-Ala, Cys594-Ser, and Leu457-Val, and an addnl. 5 residues (Ser-Ala-Ala-Gly-Thr) at the N-terminus. X-ray crystallog. yielded the atomic structural coordinates of crystalline FGFR1 and its complexes with adenylyl diphosphate, 3-[(3-(2-carboxyethyl)-4-methylpyrrol-5-yl)methylene]-2-indolinone, or 3-[4-(4-formylpiperazine-1-

L35 ANSWER 707 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ylbzenzylidenyl]-2-indolinone. Two forms of cryst. FGFR1 were obtained:
 one form (designated C2-A form) with unit cell dimensions of $a = 208.3$, $b = 57.2$, $c = 65.5$ Å and $\beta = 107.2^\circ$, and another C2-B form
 with dimensions $a = 211.6$, $b = 51.3$, $c = 66.1$ Å and $\beta = 107.7^\circ$. The overall structure of FGFR1 is bi-lobate. The
 N-terminal lobe of FGFR1 spans amino acid residues 456-567 and comprises


a curled β -sheet of five antiparallel strands and one α -helix.
 The C-terminal lobe spans amino acid residues 568-765 and comprises two
 β -strands and seven α -helices. The at. coordinates that define
 the structures of the protein tyrosine kinase and any of the compds.

bound to it are pertinent to methods for detg. the 3-dimensional structures of
 protein tyrosine kinases with unknown structure and to methods that
 identify modulators of protein tyrosine kinase functions.

IT 186611-14-3D, complex with fibroblast growth factor receptor 1
 RL: BUU (Biological use, unclassified); PRP (Properties); BIOL


(Biological study); USES (Uses)
 (crystal structures of a protein tyrosine kinase)

RN 186611-14-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)



L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 US 1997-45566P P 19970505
 US 1997-45714P P 19970505
 US 1997-45715P P 19970505
 US 1997-46843P P 19970505
 EP 1997-939480 A3 19970820
 WO 1997-US14736 W 19970820

OTHER SOURCE(S): MARPAT 128:204803
 GI



AB The invention relates to indolinone deriva. capable of modulating,
 regulating, and/or inhibiting protein kinase signal transduction. The
 compds. are useful for the treatment of diseases related to unregulated
 protein kinase signal transduction, including cell proliferative diseases
 such as cancer, atherosclerosis, arthritis, and restenosis, and metabolic
 diseases such as diabetes. Inhibitors specific to the FLK protein kinase
 can be obtained by adding chemical substituents to the 3-[(indole-3-yl)methylene]-2-indolinone system, in particular at the 1' position of
 the indole ring. Indolinone compds. that specifically inhibit the FLK and
 platelet derived growth factor protein kinases can harbor a
 tetrahydroindole or cyclopentano(b)pyrrole moiety. Indolinone compds.
 that are modified with substituents, particularly at the 5 position of
 the oxindole ring, can effectively activate protein kinases. This invention
 also features novel hydrosol. indolinone compds. that are tyrosine kinase
 inhibitors, and related products and methods. Approx. 1200 title
 compds.,
 such as I, were prepared by combinatorial condensation of certain
 (un)substituted indolinones with aldehydes at the 3-position. I gave
 complete inhibition of MET kinase at chimeric MET receptors in vitro.

IT 91822-51-4P 186611-53-OP 203988-31-2P,
 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone
 203988-38-9P, 3-[(Pyrrol-2-yl)methylidenyl]-5,7-dibromo-2-
 indolinone 203988-42-5P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203988-47-OP,
 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-iodo-2-indolinone
 203988-52-7P, 3-[(Pyrrol-2-yl)methylidenyl]-5-iodo-2-indolinone

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 ACCESSION NUMBER: 1998:147306 CAPLUS
 DOCUMENT NUMBER: 128:204803
 TITLE: Indolinone combinatorial libraries and related
 products and methods for the treatment of disease
 INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald; Hirth,
 Klaus
 Peter; Shawver, Laura Kay; et al.
 PATENT ASSIGNEE(S): Sugen, Inc., USA; Tang, Peng Cho; Sun, Li; McMahon,
 Gerald
 SOURCE: PCT Int. Appl., 293 pp.
 CODEN: PIXND2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 12
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807695	A1	19980226	WO 1997-US14736	19970820
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CN 1155838	A	19970730	CN 1996-190616	19960605
CA 2264220	A1	19980226	CA 1997-2264220	19970820
EP 929520	A1	19990721	EP 1997-939480	19970820
EP 929520	B1	20051102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001503736	T	20010321	JP 1998-510973	19970820
EP 1247803	A2	20021009	EP 2002-77564	19970820
EP 1247803	A3	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 308520	T	20051115	AT 1997-939480	19970820
ES 2251741	T3	20060501	ES 1997-939480	19970820
AU 9741556	A	19980306	AU 1997-41556	19970821
PRIORITY APPLN. INFO.:			US 1996-702232	A 19960823

US 1996-31585P	P	19961205
US 1996-31586P	P	19961205
US 1996-31588P	P	19961205
US 1996-32546P	P	19961205
US 1996-32547P	P	19961205
US 1997-45565P	P	19970505

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 203988-54-9P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203988-57-2P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203988-62-9P, 3-[(Pyrrol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203988-64-1P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203988-67-4P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203988-72-1P, 3-[(Pyrrol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203988-74-3P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203988-77-6P,
 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-[(4-(trifluoromethyl)phenyl)amino)sulfonyl]-2-indolinone 203988-82-3P, 3-[(Pyrrol-2-yl)methylidenyl]-5-[(4-(trifluoromethyl)phenyl)amino)sulfonyl]-2-indolinone 203988-84-5P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-[(4-(trifluoromethyl)phenyl)amino)sulfonyl]-2-indolinone 203988-87-8P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203988-92-5P, 3-[(Pyrrol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203988-94-7P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203988-97-0P, 3-[(1-Methylpyrrol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-02-0P, 3-[(Pyrrol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-04-2P, 3-[(3,4-Dibromo-2-methylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-05-3P,
 3-[(2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203989-08-6P, 3-[(2-(Ethoxycarbonyl)-3-[(2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203989-14-4P, 3-[(2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203989-17-7P, 3-[(2-(Ethoxycarbonyl)-3-[(2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203989-24-6P, 3-[(2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203989-27-9P, 3-[(2-(Ethoxycarbonyl)-3-[(2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203989-35-9P, 3-[(2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203989-40-6P, 3-[(2-(Ethoxycarbonyl)-3-[(2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203989-52-0P, 3-[(2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-[(4-(trifluoromethyl)phenyl)amino)sulfonyl]-2-indolinone 203989-56-4P, 3-[(2-(Ethoxycarbonyl)-3-[(2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-[(4-(trifluoromethyl)phenyl)amino)sulfonyl]-2-indolinone 203989-65-5P, 3-[(2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203989-68-8P, 3-[(2-(Ethoxycarbonyl)-3-[(2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203989-75-7P, 3-[(2,4-Dimethyl-3-(ethoxycarbonyl)pyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203989-78-0P, 3-[(2-(Ethoxycarbonyl)-3-[(2-(ethoxycarbonyl)ethyl]-4-[(ethoxycarbonyl)methyl]pyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)

indolinone 203989-88-2P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203989-98-4P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203990-08-3P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203990-18-5P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203990-28-7P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203990-38-9P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203990-48-1P, 3-[(2,4-Dimethyl-3-ethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203991-59-7P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5,7-dibromo-2-indolinone 203991-62-2P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5,7-dibromo-2-indolinone 203991-69-9P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-iodo-2-indolinone 203991-72-4P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-iodo-2-indolinone 203991-79-1P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203991-82-6P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-bromo-4-methyl-2-indolinone 203991-89-3P,

3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-92-8P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203991-99-5P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203992-02-3P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203992-09-0P

3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203992-12-5P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203992-19-2P, 3-[(4,5,6,7-Tetrahydroindol-2-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203992-22-7P, 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-5-(2-chloroethyl)-2-indolinone 203993-71-9P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5,7-dibromo-2-indolinone 203993-80-0P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-iodo-2-indolinone 203993-89-9P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203993-98-0P,

3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203994-07-4P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203994-16-5P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203994-25-6P, 3-[[1-(4-Chlorophenyl)pyrrol-2-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 203994-35-8P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone 203994-53-0P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone 203994-72-3P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203994-91-6P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203995-11-3P,

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)


3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203995-26-0P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203995-36-2P, 3-[[2-Chloro-4-(methoxycarbonyl)-3-[(methoxycarbonyl)methyl]pyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 203995-39-5P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone 203995-48-6P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone 203995-57-7P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203995-66-8P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203995-75-9P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203995-84-0P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203995-93-1P, 3-[[2-(Ethoxycarbonyl)-4-(methoxycarbonyl)-3-methylpyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 203996-03-6P, 3-[[2,4-Diethylpyrrol-5-yl]methylidenyl]-5,7-dibromo-2-indolinone 203996-13-8P, 3-[[2,4-Diethylpyrrol-5-yl]methylidenyl]-5-iodo-2-indolinone 203996-23-0P, 3-[[2,4-Diethylpyrrol-5-yl]methylidenyl]-5-bromo-4-methyl-2-indolinone 203996-33-2P, 3-[[2,4-Diethylpyrrol-5-yl]methylidenyl]-5-[(methylamino)sulfonyl]-2-indolinone 203996-43-4P, 3-[[2,4-Diethylpyrrol-5-yl]methylidenyl]-5-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-2-indolinone 203996-53-6P, 3-[[2,4-Diethylpyrrol-5-yl]methylidenyl]-5-(morpholinosulfonyl)-2-indolinone 203996-63-8P, 3-[[2,4-Diethylpyrrol-5-yl]methylidenyl]-5-(2-chloroethyl)-2-indolinone 204003-89-4P, 204003-85-0P 204003-88-3P 204003-89-4P 204003-90-7P 204003-91-8P 204003-96-3P 204003-97-4P 204004-29-5P 204004-86-4P 204004-92-2P 204004-94-4P 204005-03-8P 204005-21-0P 204005-38-9P 204005-39-0P 204005-46-9P 204005-54-9P 204005-56-1P 204005-58-3P 204005-59-4P

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and testing of indolinone combinatorial library as protein kinase inhibitors)

RN 91822-51-4 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 186611-53-0 CAPLUS

CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)




RN 203988-31-2 CAPLUS

CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203988-38-9 CAPLUS


CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 203988-42-5 CAPLUS


CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)




RN 203988-47-0 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-iodo-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 203988-52-7 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-iodo-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 203988-54-9 CAPLUS


CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203988-57-2 CAPLUS

CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-4-methyl-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 203988-62-9 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-4-methyl-3-((1H-pyrrol-2-yl)methylene)- (9CI) (CA INDEX NAME)



RN 203988-64-1 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-((3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203988-67-4 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-3-((1-methyl-1H-pyrrol-2-yl)methylene)-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-72-1 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-N-methyl-2-oxo-3-((1H-pyrrol-2-yl)methylene)-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203988-84-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene)-2,3-dihydro-2-oxo-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 203988-87-8 CAPLUS
CN Morpholine, 4-((2,3-dihydro-3-((1-methyl-1H-pyrrol-2-yl)methylene)-2-oxo-1H-indol-5-yl)sulfonyl)- (9CI) (CA INDEX NAME)




RN 203988-92-5 CAPLUS
CN Morpholine, 4-((2,3-dihydro-2-oxo-3-((1H-pyrrol-2-yl)methylene)-1H-indol-5-yl)sulfonyl)- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203988-74-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-((3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene)-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203988-77-6 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-3-((1-methyl-1H-pyrrol-2-yl)methylene)-2-oxo-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 203988-82-3 CAPLUS
CN 1H-Indole-5-sulfonamide, 2,3-dihydro-2-oxo-3-((1H-pyrrol-2-yl)methylene)-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 203988-94-7 CAPLUS
CN Morpholine, 4-((3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene)-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl)- (9CI) (CA INDEX NAME)



RN 203988-97-0 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-1,3-dihydro-3-((1-methyl-1H-pyrrol-2-yl)methylene)- (9CI) (CA INDEX NAME)




RN 203989-02-0 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-1,3-dihydro-3-((1H-pyrrol-2-yl)methylene)- (9CI) (CA INDEX NAME)




RN 203989-04-2 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-1,3-dihydro-3-((3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-05-3 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-08-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid,
5-[(5-bromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-14-4 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-35-9 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-40-6 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5-[(methylamino)sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-52-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-17-7 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5-iodo-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-24-6 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-27-9 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-56-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-5-[[4-(trifluoromethyl)phenyl]amino)sulfonyl]-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-65-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid,
5-[(1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-68-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203989-75-7 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-78-0 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 203989-88-2 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 203990-38-9 CAPLUS
CN Morpholine, 4-[(3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 203990-48-1 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203991-59-7 CAPLUS
CN 2H-Indol-2-one, 5,7-dibromo-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 203991-62-2 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 203989-98-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)



RN 203990-08-3 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 203990-18-5 CAPLUS
CN 1H-Indole-5-sulfonamide, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203990-28-7 CAPLUS


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2H-Indol-2-one, 1,3-dihydro-5-iodo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 203991-69-9 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-iodo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203991-72-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203991-79-1 CAPLUS
CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-4-methyl-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 203991-82-6 CAPLUS
CN 2H-Indol-2-one, 5-bromo-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)

10523276.trn


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 203991-89-3 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 2,3-dihydro-N-methyl-2-oxo-3-[(4,5,6,7-tetrahydro-
 1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 203991-92-8 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203991-99-5 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-
 2-yl)methylene]-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 203992-02-3 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203993-71-9 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203993-80-0 CAPLUS
 CN 2H-Indol-2-one, 3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203993-89-9 CAPLUS
 CN 2H-Indol-2-one, 5-bromo-3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 203992-09-0 CAPLUS
 CN Morpholine, 4-[(2,3-dihydro-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 203992-12-5 CAPLUS
 CN Morpholine, 4-[(3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203992-19-2 CAPLUS
 CN 2H-Indol-2-one, 5-(2-chloroethyl)-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203992-22-7 CAPLUS
 CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203993-98-0 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-
 2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203994-07-4 CAPLUS
 CN 1H-Indole-5-sulfonamide,
 3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-
 2,3-dihydro-2-oxo-N-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 203994-16-5 CAPLUS
 CN Morpholine, 4-[(3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203994-25-6 CAPLUS
CN 2H-Indol-2-one, 5-(2-chloroethyl)-3-[[1-(4-chlorophenyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203994-35-8 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-53-0 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203995-26-0 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-36-2 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-39-5 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203994-72-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-2-chloro-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203994-91-6 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 203995-11-3 CAPLUS
CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(5,7-dibromo-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203995-48-6 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-57-7 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-66-8 CAPLUS
CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[(5-bromo-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 203995-75-9 CAPLUS
 CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-2-oxo-5-[[4-(trifluoromethyl)phenyl]amino]sulfonyl]-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-84-0 CAPLUS
 CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[1,2-dihydro-2-oxo-5-(4-morpholinylsulfonyl)-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)




RN 203995-93-1 CAPLUS
 CN 1H-Pyrrole-2,4-dicarboxylic acid, 5-[[5-(2-chloroethyl)-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-3-methyl-, 2-ethyl 4-methyl ester (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 203996-33-2 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-N-methyl-2-oxo- (9CI) (CA INDEX NAME)




RN 203996-43-4 CAPLUS
 CN 1H-Indole-5-sulfonamide, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 203996-53-6 CAPLUS
 CN Morpholine, 4-[[3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203996-63-8 CAPLUS
 CN 2H-Indol-2-one, 5-[2-chloroethyl]-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204003-84-9 CAPLUS
 CN 2H-Indol-2-one, 5-amino-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)

10523276.trn


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 203996-03-6 CAPLUS
 CN 2H-Indol-2-one, 5,7-dibromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 203996-13-8 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-iodo- (9CI) (CA INDEX NAME)




RN 203996-23-0 CAPLUS
 CN 2H-Indol-2-one, 5-bromo-3-[(3,5-diethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 yl)methylene]- (9CI) (CA INDEX NAME)




RN 204003-85-0 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 204003-88-3 CAPLUS
 CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 204003-89-4 CAPLUS
 CN 2H-Indol-2-one, 5-bromo-1,3-dihydro-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 204003-90-7 CAPLUS
 CN 1H-Indole-5-carboxylic acid, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)


L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 204003-91-8 CAPLUS
CN 1H-Indole-5-carboxylic acid,
3-((3,5-diethyl-1H-pyrrol-2-yl)methylene)-2,3-
dihydro-2-oxo- (9CI) (CA INDEX NAME)



RN 204003-96-3 CAPLUS
CN 1H-Indole-5-carboxylic acid, 3-((3,5-bis(1-methylethyl)-1H-pyrrol-2-
yl)methylene)-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204003-97-4 CAPLUS
CN 1H-Indole-5-propanoic acid,
3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-2,3-
dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 204004-29-5 CAPLUS

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 204005-03-8 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-((1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl)-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204005-21-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-((1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl)-1,2,4-trimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 204005-38-9 CAPLUS
CN 2H-Indol-2-one,
5-amino-3-((4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene)-
1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204005-39-0 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-
dihydro- (9CI) (CA INDEX NAME)




L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


CN 2H-Indol-2-one,
5-amino-3-((3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene)-
1,3-dihydro- (9CI) (CA INDEX NAME)




RN 204004-86-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-((5-amino-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl)-4-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 204004-92-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-((5-chloro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl)-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204004-94-4 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-((1,2-dihydro-4-methyl-2-oxo-3H-indol-3-
ylidene)methyl)-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-
(CA INDEX NAME)




RN 204005-54-9 CAPLUS
CN 2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-4-
methyl- (9CI) (CA INDEX NAME)



RN 204005-56-1 CAPLUS
CN 2H-Indol-2-one, 5-amino-3-((3,5-diethyl-1H-pyrrol-2-yl)methylene)-1,3-
dihydro- (9CI) (CA INDEX NAME)




RN 204005-58-3 CAPLUS
CN 2H-Indol-2-one, 3-((3,5-diethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-
(9CI) (CA INDEX NAME)



RN 204005-59-4 CAPLUS
CN 2H-Indol-2-one, 3-((3,5-diethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-4-
methyl- (9CI) (CA INDEX NAME)

L35 ANSWER 708 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:735056 CAPLUS
DOCUMENT NUMBER: 129:330650
TITLE: Preparation of 3-benzylidene-2-indolinones and
analogs
INVENTOR(S): as tyrosine kinase signal transduction modulators
Tang, Peng Cho; Sun, Li; McMahon, Gerald
PATENT ASSIGNEE(S): Sugen Inc., USA
SOURCE: U.S., 34 pp., Cont.-in-part of U.S. Ser. No. 485,323.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5834504	A	19981110	US 1996-655225	19960605
US 5880141	A	19990309	US 1995-485323	19950607
JP 10504323	T	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605
PRIORITY APPLN. INFO.:				
			US 1995-485323	A2 19950607
			EP 1996-918093	A3 19960605
			JP 1997-501363	A3 19960605


OTHER SOURCE(S): MARPAT 129:330650
GI




AB Title compds. [I: R1 = H or alkyl; R2 = 2-halo-4-hydroxy- or
-alkoxyphenyl, 4-hydroxy- or -alkoxyphenyl, 4-(di)(alkyl)aminophenyl,
heteroaryl, etc.; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were
prepared Thus, oxindole was condensed with
2-chloro-4-methoxybenzaldehyde
to give I (R1 = R4-R7 = H, R2 = 2-chloro-4-methoxyphenyl, X = O). Data
for biol. activity of I were given.

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


IT 15966-93-5P 186610-93-5P 186610-94-6P
186611-14-3P 186611-15-4P 186611-16-5P
186611-29-0P 186611-30-3P 186611-31-4P
186611-35-8P 186611-36-9P 186611-37-0P
186611-38-1P 186611-39-2P 186611-48-3P
204005-03-8P 204005-46-9P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-benzylidene-2-indolinones and analogs as tyrosine
kinase signal transduction modulators)
RN 15966-93-5 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186610-93-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI)
(CA INDEX NAME)




RN 186610-94-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 186611-14-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

10523276.trn


L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-
dihydro- (9CI) (CA INDEX NAME)



RN 186611-16-5 CAPLUS
CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)




RN 186611-29-0 CAPLUS
CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-
dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester
(9CI) (CA INDEX NAME)


L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-31-4 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)




RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[(1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)

L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 186611-48-3 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 204005-03-8 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)




REFERENCE COUNT: 181 THERE ARE 181 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L35 ANSWER 709 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 186611-38-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:542764 CAPLUS
DOCUMENT NUMBER: 129:175549
TITLE: Preparation of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators
Tang, Peng Cho; Sun, Li; McMahon, Gerald
Sugen, Inc., USA
U.S., 37 pp., Cont.-in-part of U. S. Ser. No. 485,323.


INVENTOR(S):
PATENT ASSIGNEE(S):
SOURCE:
485,323.
DOCUMENT TYPE: CODEN: USXXAM
LANGUAGE: Patent
English
FAMILY ACC. NUM. COUNT: 12
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5792783	A	19980811	US 1996-655223	19960605
US 5880141	A	19990309	US 1995-485323	19950607
JP 10504323	T	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A	20000125	JP 1999-159567	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605
US 6316635	B1	20011113	US 1999-293518	19990415
US 6846839	B1	20050125	US 1999-333703	19990616
US 2002102608	A1	20020801	US 2001-897755	20010703
US 6906093	B2	20050614		

PRIORITY APPL. INFO.:
US 1995-485323 A2 19950607
EP 1996-918093 A3 19960605
JP 1997-501363 A3 19960605
US 1996-655223 A2 19960605
US 1996-655224 A2 19960605
US 1996-655226 A2 19960605
US 1996-655255 B2 19960605
US 1996-659191 A1 19960605
US 1996-702232 B2 19960823
US 1997-915366 A2 19970820
US 1998-82056P P 19980416
US 1998-212494 A2 19981215

OTHER SOURCE(S): MARPAT 129:175549
GI


L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB Title compds. [I: R1 = H or alkyl; R2 = (un)substituted (hetero)aryl; R4-R7 = H, halo, alkyl, alkoxy, etc.; X = O or S] were prepared. Thus, oxindole was condensed with 4-pyridinecarboxaldehyde to give I (R1, R4-R7 = H).


IT H, R2 = 4-pyridinyl, X = O. Data for biol. activity of I were given.
 15966-93-5P 91822-51-4P 186610-93-5P
 186610-94-6P 186611-14-3P 186611-15-4P
 186611-16-5P 186611-17-6P 186611-29-0P
 186611-30-3P 186611-31-4P 186611-35-8P
 186611-36-9P 186611-37-0P 186611-38-1P
 186611-39-2P 186611-48-3P 186611-56-3P
 186611-67-6P 204005-46-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 3-(hetero)arylmethylene-2-indolinones as tyrosine kinase signal transduction modulators)

RN 15966-93-5 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 91822-51-4 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]- (CA INDEX NAME)


L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186611-16-5 CAPLUS
 CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-17-6 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 CAPLUS
 CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186610-93-5 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-14-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)


L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186611-31-4 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-35-8 CAPLUS
 CN 2H-Indol-2-one, 3-[(1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-36-9 CAPLUS
 CN 2H-Indol-2-one, 3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-37-0 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-38-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-((1-methyl-1H-pyrrol-2-yl)methylene)- (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1998:429042 CAPLUS
DOCUMENT NUMBER: 129:117426
TITLE: Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases
AUTHOR(S): Sun, Li; Tran, Ngoc; Tang, Flora; App, Harald; Hirth, Peter; McMahon, Gerald; Tang, Cho
CORPORATE SOURCE: SUGEN Inc, Redwood City, CA, 94063, USA
SOURCE: Journal of Medicinal Chemistry (1998), 41(14), 2588-2603
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 3-Substituted indolin-2-ones have been designed and synthesized as a novel class of tyrosine kinase inhibitors which exhibit selectivity toward different receptor tyrosine kinases (RTKs). These compounds have been evaluated for their relative inhibitory properties against a panel of RTKs in intact cells. By modifying the 3-substituted indolin-2-ones, we have identified compounds which showed selective inhibition of the ligand-dependent autophosphorylation of various RTKs at submicromolar levels in cells. Structure-activity analysis for these compounds and their relative potency and selectivity to inhibit particular RTKs has determined that (1) 3-[(five-membered heteroaryl ring)methylidenyl]indolin-2-ones are highly specific against the VEGF (Flk-1) RTK activity, (2) 3-[(substituted benzylidenyl)indolin-2-ones containing bulky group(s) in the Ph ring at the C-3 position of indolin-2-ones showed high selectivity toward the EGF and Her-2 RTKs, and (3) the compound containing an extended side chain at the C-3 position of the indolin-2-one exhibited high potency and selectivity when tested against the PDGF and VEGF (Flk-1) RTKs. Recent published crystallographic data for two of these 3-substituted indolin-2-ones provides a rationale to suggest that these compounds may bind in the ATP binding pocket of RTKs. The structure-activity analysis supports the use of subsets of these compounds as specific chemical leads for the development of RTK-specific drugs with broad application for the treatment of human diseases.
IT 194413-58-6P 210303-07-4P 210303-45-0P
210303-46-1P 210303-47-2P 210303-48-3P
210303-49-4P 210303-50-7P 210303-51-8P
210303-52-9P 210303-53-0P 210303-54-1P
210303-55-2P 210303-56-3P 210303-57-4P
210303-58-5P 210303-59-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and evaluation of 3-substituted indolin-2-ones as inhibitors of selective growth factor receptors)
RN 194413-58-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (CA INDEX NAME)

10523276.trn


L35 ANSWER 710 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 186611-56-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



RN 186611-67-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)




RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



REFERENCE COUNT: 179 THERE ARE 179 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Double bond geometry as shown.




RN 210303-07-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210303-45-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-4-methyl-3-[(1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210303-46-1 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RN 210303-47-2 CAPLUS
 CN 2H-Indol-2-one, 6-fluoro-1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210303-48-3 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-49-4 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 2-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210303-50-7 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 210303-54-1 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210303-55-2 CAPLUS
 CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-56-3 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 210303-57-4 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3-(1H-pyrrol-2-ylmethylene)-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 210303-51-8 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(2)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210303-52-9 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-6-fluoro-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 210303-53-0 CAPLUS
 CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L35 ANSWER 711 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 210303-58-5 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-4-methyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 210303-59-6 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-methyl-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L35 ANSWER 712 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:640690 CAPLUS
 DOCUMENT NUMBER: 127:314804
 TITLE: Assays for KDR/FLK-1 receptor tyrosine kinase inhibitors, and use of the inhibitors for treatment of
 INVENTOR(S): Hirth, Klaus P.; McMahon, Gerald; Shawver, Laura K.
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9734920	A1	19970925	WO 1997-US3378	19970304
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: CH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9720667	A	19971010	AU 1997-20667	19970304
PRIORITY APPLN. INFO.:			US 1996-621734	A 19960321
			WO 1997-US3378	W 19970304

AB Processes are disclosed for the identification of compds. and pharmaceutical compns. capable of selectively and potently inhibiting KDR/FLK-1 tyrosine kinase signal transduction in order to inhibit vasculogenesis and/or angiogenesis. The invention also relates to compds. and compns. identified using the methods of the invention and the use thereof for the treatment of disease relating to inappropriate vasculogenesis and/or angiogenesis. The invention provides an assay cascade comprised of several "filter steps" of increasing selectivity which identify a limited subset of candidate compds. affecting the VEGF receptor on the mol. level.
 IT 91822-51-4, SU 4314 204005-46-9, SU 5416
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES (Uses) (KDR/FLK-1 receptor tyrosine kinase inhibitor identification assay, and use of compds. for treatment of vasculogenesis- and angiogenesis-related diseases)
 RN 91822-51-4 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)


L35 ANSWER 713 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:322412 CAPLUS
 DOCUMENT NUMBER: 127:44439
 TITLE: Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
 AUTHOR(S): Mohammadi, Moosa; McMahon, Gerald; Sun, Li; Tang, Hirth, Peter; Yeh, Brian K.; Hubbard, Stevan R.; Schlessinger, Joseph
 CORPORATE SOURCE: Dep. Pharmacology, New York Univ. Med. Center, New York, NY, 10016, USA
 SOURCE: Science (Washington, D. C.) (1997), 276(5314), 955-960
 CODEN: SCIEAS; ISSN: 0036-8075
 PUBLISHER: American Association for the Advancement of Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A new class of protein tyrosine kinase inhibitors was identified that is based on an oxindole core (indolinones). Two compds. from this class inhibited the kinase activity of fibroblast growth factor receptor 1 (FGFR1) and showed differential specificity toward others receptor tyrosine kinases. Crystal structures of the tyrosine kinase domain of FGFR1 in complex with the two compds. were determined. The oxindole occupies the sites in which the adenine of ATP binds, whereas the moieties that extend from the oxindole contact residues in the hinge region between the two kinase lobes. The more specific inhibitor of FGFR1 induces a conformational change in the nucleotide-binding loop. This structural information will facilitate the design of new inhibitors for use in the treatment of cancer and other diseases in which cell signaling by tyrosine kinases plays a crucial role in disease pathogenesis.
 IT 186611-14-3, SU 5402
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (inhibitor; structure of tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors)
 RN 186611-14-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L35 ANSWER 712 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 204005-46-9 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)



L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1997:140244 CAPLUS
 DOCUMENT NUMBER: 126:139901
 TITLE: Indolinone compounds capable of modulating tyrosine kinase signal transduction
 INVENTOR(S): Tang, Peng Cho; Sun, Li; McMahon, Gerald
 PATENT ASSIGNEE(S): Sugen, Inc., USA
 SOURCE: PCT Int. Appl., 133 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 12
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9640116	A1	19961219	WO 1996-US8903	19960605
W: AL, AM, AU, A2, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5880141	A	19990309	US 1995-485323	19950607
CA 2192797	A1	19961219	CA 1996-2192797	19960605
CA 2192797	C	20060516		
AU 9660441	A	19961230	AU 1996-60441	19960605
AU 9660597	B2	19990617		
EP 769947	A1	19970502	EP 1996-918093	19960605
EP 769947	B1	20010502		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9606410	A	19971230	BR 1996-6410	19960605
JP 10504323	T	19980428	JP 1997-501363	19960605
JP 3231044	B2	20011119		
HU 9701694	A2	19990628	HU 1997-1694	19960605
EP 934931	A2	19990811	EP 1999-103667	19960605
EP 934931	A3	19991020		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
JP 2000026412	A	20000125	JP 1999-159567	19960605
AT 200863	T	20010515	AT 1996-918093	19960605
ES 2159741	T3	20011016	ES 1996-918093	19960605
PT 769947	T	20011031	PT 1996-918093	19960605
NO 9605377	A	19970212	NO 1996-5377	19961213
NO 311355	B1	20011119		
HK 1001121	A1	20070316	HK 1998-100009	19980102
HK 1011933	A1	20020118	HK 1998-113193	19981211
GR 3036315	T3	20011031	GR 2001-401166	20010731
PRIORITY APPLN. INFO.:			US 1995-485323	A 19950607
			EP 1996-918093	A3 19960605
			JP 1997-501363	A3 19960605
			WO 1996-US8903	W 19960605

OTHER SOURCE(S): MARPAT 126:139901
 AB The present invention relates to organic mols. capable of modulating tyrosine

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. Representatives of the 5 different classes of compds. described are SU 4932 [3-(2-chloro-4-hydroxybenzylidene)-2-indolinone], SU 4312 [3-(4-dimethylaminobenzylidene)-2-indolinone], SU 5416 [3-[(2,4-dimethylpyrrol-5-yl)methylene]-2-indolinone], SU 5204 [3-(2-ethoxybenzylidene)-2-indolinone], and SU 4942 [3-(4-bromobenzylidene)-2-indolinone]. Diseases which these compds. and their pharmaceutically acceptable preps. may be effective against include arthritis, hepatic cirrhosis, diabetic nephropathy and psoriasis.


IT 15966-93-5P, SU 5408 91822-51-4P, SU 4314
 186610-93-5P, SU 5404 186610-94-6P, SU 5406
 186611-14-3P, SU 5402 186611-15-4P, SU 5403
 186611-16-5P, SU 5405 186611-17-6P, SU 5407
 186611-29-0P, SU 5453 186611-30-3P, SU 5454
 186611-31-4P, SU 5455 186611-32-5P, SU 5456
 186611-33-6P, SU 5459 186611-34-7P, SU 5460
 186611-35-8P, SU 5461 186611-36-9P, SU 5462
 186611-37-0P, SU 5463 186611-38-1P, SU 5464
 186611-39-2P, SU 5465 186611-48-3P, SU 5477
 186611-49-4P, SU 5478 186611-50-7P, SU 5479
 186611-53-0P, SU 5612 186611-54-1P, SU 5613
 186611-56-3P, SU 5614 186611-65-4P, SU 5624
 186611-66-5P, SU 5625 186611-67-6P, SU 5626
 204005-46-9P, SU 5416
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indolinones capable of modulating tyrosine kinase signal transduction)

RN 15966-93-5 CAPLUS
 CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 91822-51-4 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)


L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186611-16-5 CAPLUS
 CN 1H-Pyrrole-2-carboxaldehyde, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3,4-dimethyl- (9CI) (CA INDEX NAME)



RN 186611-17-6 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-29-0 CAPLUS
 CN 2H-Indol-2-one, 3-[(3-ethyl-4,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-30-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186610-93-5 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186610-94-6 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,4-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-14-3 CAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 186611-15-4 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,4-dibromo-5-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)


L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186611-31-4 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-ethyl-3-methyl- (9CI) (CA INDEX NAME)



RN 186611-32-5 CAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-diiodo-4-methyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-33-6 CAPLUS
 CN 1H-Pyrrole-3-acetic acid, 2-chloro-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-(methoxycarbonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 186611-34-7 CAPLUS
 CN 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 186611-35-8 CAPLUS
CN 2H-Indol-2-one, 3-[(1-(3,5-dichlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-36-9 CAPLUS
CN 2H-Indol-2-one, 3-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-37-0 CAPLUS
CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-4-methyl-, ethyl ester (9CI) (CA INDEX NAME)


L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186611-50-7 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-4-(1-methylethenyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 186611-53-0 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186611-54-1 CAPLUS
CN 2H-Indol-2-one, 5-chloro-1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)




RN 186611-56-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)


L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186611-38-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(1-methyl-1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-39-2 CAPLUS
CN 1H-Pyrrole-3-propanoic acid, 2-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-5-(ethoxycarbonyl)-4-(2-ethoxy-2-oxoethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 186611-48-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-ethyl-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 186611-49-4 CAPLUS
CN 2H-Indol-2-one, 3-[(5-ethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (9CI) (CA INDEX NAME)


L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 186611-65-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-5-nitro-3-[(1H-pyrrol-2-yl)methylene]- (9CI) (CA INDEX NAME)



RN 186611-66-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methyl-1H-pyrrol-2-yl)methylene]-5-nitro- (9CI) (CA INDEX NAME)




RN 186611-67-6 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-nitro- (9CI) (CA INDEX NAME)



RN 204005-46-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- (CA INDEX NAME)

L35 ANSWER 714 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




L35 ANSWER 715 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1996:746204 CAPLUS
 DOCUMENT NUMBER: 126:18783
 TITLE: Substituted indolymethylene-oxindole analogs as tyrosine kinase inhibitors
 INVENTOR(S): Battistini, Carlo; Ballinari, Dario; Ermoli, Antonella; Penco, Sergio; Viooglio, Sergio
 PATENT ASSIGNEE(S): Pharmacia S.P.A., Italy
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9632380	A1	19961017	WO 1996-EP1165	19960314
W: JP, US				
RM: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 764152	A1	19970326	EP 1996-907500	19960314
EP 764152	B1	20020731		
R: DE, ES, FR, GB, IT, SE				
JP 10501821	T	19980217	JP 1996-530667	19960314
ES 2181875	T3	20030301	ES 1996-907500	19960314
US 5849710	A	19981215	US 1996-750208	19961204
PRIORITY APPLN. INFO.:			GB 1995-7298	A 19950407
			WO 1996-EP1165	W 19960314

OTHER SOURCE(S): MARPAT 126:18783
 GI



II

AB Indol-3-ylmethylene-2-oxindole derivs. I and their pharmaceutically acceptable salts are disclosed [wherein 1 or 2 of R, R1, R2, and R3 = X(CH2)mNH2, X(CH2)mNR4R5, X(CH2)mNHR6, NHC(:NH)NH2, NHC(:NH)NR4R5, NHC(:NH)NHR6, N:CHNH2, N:CHNR4R5, N:CHNHR6, X(CH2)mCOR7, COR8, COR9,

L35 ANSWER 715 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


YCOY'R9, NHR6, NHR10 group; remaining groups within R and R1-R3 = H, halo, amino, OH, alkyl, alkoxy, CO2H, alkoxycarbonyl, alkanoyloxy, cyano, NR4R5;
 X = O, S, NH; m = 1-4; 1 of R4 and R5 = H or alkyl, and other = alkyl; or NR4R5 forms satd. monoheterocycle; R6 = alkanoyl, 1- to 3-residue (un)substituted peptidyl; R7 = OH, amino, alkoxy, NR4R5; Ra = amino terminus of 1- to 3-unit peptidyl; R8 = alkoxy, phenylalkoxy, (CH2)nNH2, (CH2)nNR4R5, (CH2)nNHR6; n = 1-2; Y, Y' = NH, O; R9 = Ph, alkyl, phenylalkyl; R10 = mono-, di- or trihydroxyalkyl]. I have tyrosine kinase

inhibiting activity, and are useful as antiproliferative, antimetastatic, anticancer, antiatheromatous, anti-Alzheimer, and immunomodulating agents.

For example, 2-indolinone reacted with BrCH2COBr and AlCl3 to give the 5-(2-bromoacetyl) deriv., which underwent amination with piperidine and then condensation with indole-3-carboxaldehyde, to give title compd. II (FCE 28484). In tests for inhibition of p45 v-abl kinase and K562 leukemia cells in vitro, II had IC50 of 0.78 and 4.82 μM, resp.

IT 184020-79-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of (indolymethylene)oxindole analogs as tyrosine kinase inhibitors)

RN 184020-79-9 CAPLUS
 CN Methanimidamide, N'-[2-[[[1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-1H-indol-5-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




L35 ANSWER 716 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1992:490138 CAPLUS
 DOCUMENT NUMBER: 117:90138
 TITLE: Preparation of 3-(arylmethylene)oxindoles and analogs as gastrin releasing peptide antagonists
 INVENTOR(S): Nakanishi, Susumu
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9207830	A2	19920514	WO 1991-US4978	19910718
WO 9207830	A3	19920625		
W: CA, FI, JP, US				
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
PRIORITY APPLN. INFO.:			US 1990-605220	A2 19901029

OTHER SOURCE(S): MARPAT 117:90138
 GI




II

AB Title compds. [I; RR2 = arylmethylene, NHCONHCO; R1 = Me, Et, (halo)benzyl; R3 = alkyl, halo, groups cited for R4; R4 = H, 5- or 6-O(CH2)nOH, -O(CH2)nCO2H, -OCH2CH(OH)CH2OH, -OCH2Ph, etc.; n = 0-4] were prepared as gastrin releasing peptide antagonists (no data). Thus, 4-(MeO)C6H4NH2 was condensed with ClCH2COCl and the product cyclized to give 5-hydroxyoxindole which was condensed with 3,5-bis(tert-butyl)-4-hydroxybenzaldehyde and the product O-alkylated with 2-(MeO2C)C6H4CH2Br

to give, after saponification, title compound II.
 IT 142642-28-2P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as gastrin releasing peptide antagonist)

RN 142642-28-2 CAPLUS
 CN Benzoic acid, 2-[[[1-ethyl-2,3-dihydro-2-oxo-3-(1H-pyrrol-2-ylmethylene)-1H-indol-5-yl]oxy]methyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 716 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



L35 ANSWER 717 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN
 ACCESSION NUMBER: 1986:478828 CAPLUS
 DOCUMENT NUMBER: 105:78828
 TITLE: (Aminohydroxypropoxy)oxindole derivatives
 INVENTOR(S): Michel, Helmut; Kampe, Wolfgang; Strein, Klaus;
 Bartsch, Wolfgang
 PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 36 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3426419	A1	19860123	DE 1984-3426419	19840718
EP 170117	A1	19860205	EP 1985-108579	19850710
EP 170117	B1	19910130		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 60582	T	19910215	AT 1985-108579	19850710
JP 61036259	A	19860220	JP 1985-156191	19850717
US 4826847	A	19890502	US 1986-948422	19861230
PRIORITY APPLN. INFO.:			DE 1984-3426419	A 19840718
			EP 1985-108579	A 19850710
			US 1985-755497	A1 19850716


OTHER SOURCE(S): CASREACT 105:78828; MARPAT 105:78828
 GI



AB Oxindoles I [R1 = C2-10 nitroalkyl; X = H, C1-6 alkyl; Y = H, C1-6 alkyl; CR2R3R4; R2 = H; R2X = bond; R3 = H, C1-6 alkyl; R4 = C1-6 alkyl, cycloalkyl, (un)substituted aryl or heteroaryl; XY complete a C3-7 cycloalkyl ring], having nitrate-like and β -blocking activity and thus useful in treating heart and circulation disorders (no data), were prepared by 5 methods. 4-(2,3-Epoxypropoxy)indolinone in MeOH was treated

L35 ANSWER 717 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)
 with O3NCH2CH2CHMeNH2 3 h at room temp. to give 421 II, isolated as the benzoate.


IT 103552-24-5P 103552-25-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as β -blocker)
 RN 103552-24-5 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[[1-methyl-3-(nitrooxy)propyl]amino]propoxy]-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 103552-25-6 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[[1-methyl-3-(nitrooxy)propyl]amino]propoxy]-3-(1H-pyrrol-2-ylmethylene)-, (2E)-2-butenedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 103552-24-5
 CMF C20 H24 N4 O6



CM 2

CRN 110-17-8
 CMF C4 H4 O4


Double bond geometry as shown.



IT 103552-26-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with methylnitratopropylamine)
 RN 103552-26-7 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-4-(oxiranylmethoxy)-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)

10523276.trn


L35 ANSWER 717 OF 723 CAPLUS COPYRIGHT 2007 ACS ON STN (Continued)



L35 ANSWER 718 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1985:131907 CAPLUS
 DOCUMENT NUMBER: 102:131907
 TITLE: 2-Indolinone derivatives, pharmaceuticals containing them, and their intermediate products
 INVENTOR(S): Michel, Helmut; Marzenell, Klaus; Kampe, Wolfgang; Bartach, Wolfgang; Schaumann, Wolfgang
 PATENT ASSIGNEE(S): Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 35 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3310891	A1	19840927	DE 1983-3310891	19830325
EP 121176	A1	19841010	EP 1984-103045	19840320
EP 121176	B1	19870930		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 30021	T	19871015	AT 1984-103045	19840320
JP 59176253	A	19841005	JP 1984-54612	19840323
US 4642309	A	19870210	US 1985-780704	19850926
PRIORITY APPLN. INFO.:			DE 1983-3310891	A 19830325
			EP 1984-103045	A 19840320
			US 1984-592616	A1 19840323


OTHER SOURCE(S): CASREACT 102:131907; MARPAT 102:131907
 GI




AB Indolinones I [R = alkyl, (un)substituted Ph; R₁ = R₂ = H, R₁R₂ = bond; R₃ = (un)substituted Ph, heterocyclyl; Z = alkylene, O, S, bond] were prepared as antihypertensives and β-sympatholytics (no data). Thus, Et 2-(2-oxiranylmethyl)-6-nitrobenzeneacetate was treated Me₂CHNH₂ and cyclized by hydrogenation over Pd-C to give 891 4-[2-hydroxy-3-(isopropylamino)propoxy]-2-indolinone. The latter was condensed with 2-HOC₆H₄CHO to give 471 I (R = Me₂CH, R₁R₂ = Z = bond, R₃ = 2-HOC₆H₄, which was hydrogenated over Pd-C to give 341 I.BrOH [R = Me₂CH, R₁ = R₂ = H, R₃ = 2-HOC₆H₄, Z = bond].
 IT 94533-08-1P 94533-25-2P 94533-28-5P

L35 ANSWER 718 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


PAGE 2-A



RN 94533-28-5 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[(2-phenoxyethyl)amino]propoxy]-3-(1H-indol-2-ylmethylene)- (9CI) (CA INDEX NAME)




L35 ANSWER 718 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 94533-08-1 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[(1-methylethylamino)propoxy]-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



RN 94533-25-2 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-4-[2-hydroxy-3-[(2-(4-hydroxyphenoxy)ethyl)amino]propoxy]-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)

PAGE 1-A




L35 ANSWER 719 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1969:403203 CAPLUS
 DOCUMENT NUMBER: 71:3203
 TITLE: Indole chemistry. VI. α,β'-Diindolylmethanes and α,β'-diindolylmethenes


AUTHOR(S): Von Döbeneck, Henning; Wolkenstein, Dieter; Blankenstein, Guenter
 CORPORATE SOURCE: Tech. Hochsch. Muenchen, Munich, Fed. Rep. Ger.
 SOURCE: Chemische Berichte (1969), 102(4), 1347-56
 CODEN: CHBEAM; ISSN: 0009-2940
 DOCUMENT TYPE: Journal
 LANGUAGE: German

GI For diagram(s), see printed CA Issue.
 AB Urorosin was prepared by polycondensation of indol-3-ylglycolic acid, followed by oxidation with the formation of the α,β'-diindolylmethene chromophore. α,β'-Diindolylmethanes (I) were prepared by the reaction of α- and β-unsubstituted indoles with glyoxylic acid; α,β'-diindolylmethenes, from α-formylindoles and β-unsubstituted indoles. Oxo-β,β'- and oxo-α,β'-diindolylmethenes were prepared from β- and α-formylindoles and oxindoles.

IT 22813-86-1P 22813-87-2P 22813-88-3P
 22813-89-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 22813-86-1 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-indol-2-ylmethylene)- (9CI) (CA INDEX NAME)




RN 22813-87-2 CAPLUS
 CN 2-Indolinone, 3-(indol-2-ylmethylene)-1-methyl- (8CI) (CA INDEX NAME)




RN 22813-88-3 CAPLUS
 CN 2-Indolinone, 3-[(1,3-dimethylindol-2-yl)methylene]- (8CI) (CA INDEX NAME)

L35 ANSWER 719 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 22813-89-4 CAPLUS
CN 2-Indolinone, 3-[(1,3-dimethylindol-2-yl)methylene]-1-methyl- (8CI) (CA INDEX NAME)



L35 ANSWER 720 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1968:496372 CAPLUS
DOCUMENT NUMBER: 69:96372
TITLE: Stokvis reactions. XVII. Vilsmeier reactions with pyrrole and pyrrolone derivatives
AUTHOR(S): Schnierle, Franz; Reinhard, Horst; Dieter, Norbert; Lippacher, Eberhard; Von Dobeneck, Henning
CORPORATE SOURCE: Tech. Hochsch. Muenchen, Munich, Fed. Rep. Ger.
SOURCE: Justus Liebig's Annalen der Chemie (1968), 715, 90-7
CODEN: JLABCF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 69:96372


AB Vilsmeier formylation of 4-methyl-3-acetyl-2-methoxycarbonylpyrrole gave 4-methyl-2-methoxycarbonyl-3-(1-chloro-3-dimethylimmonio-1-propenyl)pyrrole perchlorate. Formylation of I (R = Me or Et) in the presence of POX3 (X = Br or Cl) gave II. 3-methyl-4-(R-substituted)-3-pyrrolin-2-one, treated as above, gave 3-methyl-4-(R-substituted)-5-(X-substituted)-2-formylpyrrole. The Vilsmeier reactions of 4-methyl-3-(R-substituted)-3-pyrrolin-2-one with ClCOCOC1 gave III. 16 references.

IT 19713-94-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 19713-94-1 CAPLUS

CN 2-Indolinone, 3-[(5-chloro-3,4-dimethylpyrrol-2-yl)methylene]- (8CI) (CA INDEX NAME)



L35 ANSWER 721 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1967:433817 CAPLUS
DOCUMENT NUMBER: 67:33817
TITLE: Isoindigo dyes of the pyrrole series
AUTHOR(S): Treibs, Alfred; Jacob, Karl; Dietl, Anton
CORPORATE SOURCE: Tech. Hochsch. Munich, Munich, Fed. Rep. Ger.
SOURCE: Justus Liebig's Ann. Chem. (1967), 702, 112-30
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 67:33817

GI For diagram(s), see printed CA Issue.
AB The dye obtained by lactam ring closure of PhCOCH2CH2CO2H (I) has the structure (II) of a phenylpyrrole-isoindigo (P-II) proposed by Kugel, and is identical with the compound obtained from the O analog, the Pechmann dye

III. In addition to P-II, 4-(3-carboxy-1-phenylpropylidene)-2-phenyl-2-pyrrolin-5-one is formed by condensation of 2-phenyl-2-pyrrolin-5-one

with I, which can also be converted into P-II via a readily proceeding retrocrotization-retroaldol reaction. New methods for the synthesis of pyrrole-indole-isoindigo derivs. (e.g. IV, X = O, NH, and NMe) are described. The pyrrolylpyrrolinones V (R = CO2Et) (VI) and V (R = H) (VII) and the pyrrolylpyrrole-isoindigo derivs. VIII (R = CO2Et) (IX)


and VIII (R = H) (X) prepared from VI and VII were obtained; IX and X are derivs. of an α , β , α -linked tetrapyrrole.

IT 15966-93-5P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 15966-93-5 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



L35 ANSWER 722 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1964:469030 CAPLUS
DOCUMENT NUMBER: 61:69030
ORIGINAL REFERENCE NO.: 61:11958b-c
TITLE: Dinitrocarbazoles
AUTHOR(S): Grotta, Henry M.; Riggle, Charles J.; Bearse, Arthur E.
CORPORATE SOURCE: Battelle Mem. Inst., Columbus, OH
SOURCE: Journal of Organic Chemistry (1964), 29(8), 2474-6
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 61:69030

GI For diagram(s), see printed CA Issue.

AB Nitration of carbazole (I) in AcOH at 75° with 3 equivs. 70% HNO3 gave 3,6-dinitrocarbazole (II). II was reduced and converted by the Sandmeyer reaction to the 3,6-dichlorocarbazole. The alc.-alkali-insol. material from II afforded 1,6-dinitrocarbazole (III). III was converted to the unknown 1,6-dichlorocarbazole (IV). IV was also synthesized from 2,5-dichloronitrobenzene and 2-chloro-aniline. Nitration with NaNO2 and

2 equivs. HNO3 gave a similar ratio of II and III.

IT 91822-51-4P, 2-Indolinone, 3-(pyrrol-2-ylmethylene)-


92148-69-1P, 2-Indolinone, 1-methyl-3-(pyrrol-2-ylmethylene)-

RL: PREP (Preparation)

(preparation of)


RN 91822-51-4 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)




RN 92148-69-1 CAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-1-methyl-3-(1H-pyrrol-2-ylmethylene)- (9CI) (CA INDEX NAME)



L35 ANSWER 723 OF 723 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 1964:469029 CAPLUS
 DOCUMENT NUMBER: 61:69029
 ORIGINAL REFERENCE NO.: 61:11957h,11958a-b
 TITLE: Reduction of some oxindolylidene derivatives to
 3-substituted oxindoles by sodium borohydride
 AUTHOR(S): Elliott, I. W.; Rivers, P.
 CORPORATE SOURCE: Fisk Univ., Nashville, TN
 SOURCE: Journal of Organic Chemistry (1964), 29(8), 2438-40
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 AB 3a-Picolyloxindole (I) was prepared by condensation of
 2-pyridinecarboxaldehyde with oxindole in the presence of piperidine.
 Oxindole and 2-pyridinecarboxaldehyde condensed in MeOH gave
 3-oxindolyl-2-pyridylcarbinol. I treated with NaBH₄ gave
 3a-picolyloxindole. Similar reduction of 3-benzylideneoxindole (II)
 with NaBH₄ gave 3-benzylloxindole (III). III was also obtained from II by
 treatment with Na dithionite. Oxindole treated with cyclohexanone and
 piperidine gave cyclohexylideneoxindole (IV). IV hydrogenated over 10%
 Pd-C gave 3-cyclohexylloxindole (V). Reduction of IV with NaBH₄ also
 gave V.
 IT Reduction of isoindigo with NaBH₄ gave leucoisoindigo.
 91822-51-4P, 2-Indolinone, 3-(pyrrol-2-ylmethylene)-
 92148-69-1P, 2-Indolinone, 1-methyl-3-(pyrrol-2-ylmethylene)-
 RL: PREP (Preparation)
 (preparation of)
 RN 91822-51-4 CAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-3-(1H-pyrrol-2-ylmethylene)- (CA INDEX NAME)



RN 92148-69-1 CAPLUS
 CN 2H-Indol-2-one, 1-methyl-3-(1H-pyrrol-2-ylmethylene)- (9CI)
 (CA INDEX NAME)



=> log h

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
123.95	521.23

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-17.94	-19.45

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:06:22 ON 25 MAY 2007